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A growing number of patients afected by cancer and its treatments need to improve their 
physical  welbeing  and  quality  of life. To  address these  vital  needs,  cancer rehabilitation 
programs have  been  developed to  help with the  patients’  symptom burden and physical and 
psychological status. However, these programs are missing a personalized patient assessment 
and a systematic categorical intake system placing patients into rehabilitation pathways based 
upon  disease  severity. This  study retrospectively  evaluated the impact  of the interdisciplinary 
Cancer  Rehabilitation (CARE) Program on health-related  quality  of life,  by  monitoring the 
folowing  assessments: the  abridged  Patient-Generated  Subjective  Global  Assessment, 
Edmonton  Symptom  Assessment  System,  Fatigue  Symptom Inventory,  Distress  Screening 
Tool,  and the Modified  Community  Healthy  Activities  Model  Program for  Seniors.  Cancer 
outpatients (n=115)  were  divided into three  pathways (Restorative,  Supportive  or  Cachexia) 
based  on their  prognosis  and needs. The assessments  were  measured  between  and  within 
each  pathway;  at  baseline,  pre-post  program  and  over time. Baseline  diferences  by  pathway 
were determined by a series of general linear models. Mixed models were used to examine time 
diferences from pre-post program in al pathways and, as a function of pathway over folow up 
visits. Overal, patients showed a significant improvement in total malnutrition score and a trend 
of  progress for  appetite  status,  on the  account  of the  program. Quality of life  and  symptom 
profile varied across cancer patients at diferent stages of their disease. Interdisciplinary cancer 
rehabilitation  programs  need to  be  organized  around those  characteristics to  personalize their 
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   Table 1. Abbreviations of Terms 
ACS Anorexia-Cachexia Syndrome 
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Satisfaction - Patient Satisfaction 
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IES-R Impact of Event Scale - Revised 
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SAS Statistical Analysis Software 
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WBC White Blood Cel 
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1.0    Introduction: 
In 2012, the worldwide incidence of cancer increased to approximately 14 milion cases 
per  year,  and throughout the  next  20  years, it is  anticipated to  progressively increase to  22 
milion. Although the annual cancer mortality rate has been forecasted to increase from 8.2 to 
13 milion cases, more people wil be living with cancer (Gaudin, 2014). Within Canada, roughly 
2 in  5  Canadians  wil  develop  cancer,  and  1 in  4  wil  die from it.  Perhaps  more importantly, 
nearly two thirds (63%)  of  Canadians  with  cancer  wil  survive  at least  5  years  after their 
diagnosis,  and this  survival  statistic  wil  most likely increase in the  years to  come (Canadian 
Cancer  Society,  2015). In the  province  of  Quebec,  also in  2015, there  were  50,100  newly 
diagnosed cases of cancer, and about 20,900 people died of cancer (Canadian Cancer Society: 
Quebec, 2015). 
The worldwide, national and local trends of increasingly higher cancer incidence rates, 
from the last  30  years,  are  chiefly  a result  of  demographic  growth  and the  aging  of the 
population.  With  people living longer, there  will  be  a  growing  number  of  patients that  wil fal 
within  a  new  cohort treatment  category  of  geriatric  oncology (Quebec  and  Canadian  Cancer 
Statistics,  2013).  Earlier  diagnoses  and  more  efective  cancer treatments  have resulted in 
greatly improved survival rates thus alowing patients to live longer with the disease. However, 
as a consequence of living longer, the survivors are being chalenged with other co-morbidities 
(e.g., cardiovascular  disease,  diabetes)  as  wel  as the  burden  of  numerous  cancer-related 
symptoms and secondary complications related to cancer and its treatments (Custodio, 2011). 
A larger majority of cancer patients wil most likely experience a decline in physical functioning 
or QoL throughout the course of their disease (Franklin et al., 2010). Considering that cancer is 
now being recognized as a long-term ilness dependent upon disease management, there is a 
great need for specific rehabilitation interventions for cancer survivors (Spence et al., 2010) with 
evidence-based practices that combine clinical/professional expertise, patient values and input, 
and the  best research  evidence.  Figure  1  describes  how these important  components  are 









Figure 1: Evidence-Based Practices (EBP) Process 
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There is  an  accumulating  amount  of  scientific  evidence  demonstrating that  cancer 
rehabilitation is  becoming  an  essential  component  of the  supportive  care to  alow  patients to 
experience a beter QoL and improve their physical and psychological status (McIntyre, 2012; 
Gamble et al., 2011). Though, psychological problems are often less evident or acknowledged 
by the physician or patient, they occur just as often as physical struggles in cancer patients. In 
addition, physical ability decline oftentimes further provokes psychological distress (Stein et al., 
2008). 
The health care system recognizes that patients afected by cancer and its treatments, 
require improvements in functional  status  and  QoL. However, there  are  minimal resources 
available and a wide diversity of cancer rehabilitation programs. Many have debated that these 
programs  should  be  provided outside of the cancer clinics in a tertiary care hospital seting 
because it is  costly  with  unknown  outcomes (Berg et al., 2014). The prominent issues 
surrounding the lack  of  available  cancer rehabilitation  programs include: lack  of funding  and 
resources, lack of accessibility, no oficial definition of cancer rehabilitation services, lack of 
specific implementation  plans, lack  of trained  cancer rehabilitation  physicians  and therapists, 
and failure to educate referring health care professionals (Berg et al., 2014). Additional issues 
involve  a  greater focus  on  wel-established  preventive  or  curative treatments, time  constraints 
and a lack of coordination for this type of care (Cole et al., 1999). Seeing as the high demand 
for cancer rehabilitation is currently not being satisfied by the public health care system, further 
resources are required (Berg et al., 2014). Private foundations can become more commited to 
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multimodal care, and scientists should help public funding sources acknowledge the importance 
of research in multimodal care (MacDonald et al., 2013). 
Fortunately, there  has  been  a  gradual rise in  promoting  patient  centered  cancer  care 
over the  past forty  years.  Health  care  professionals  are  starting to take into  account  patients’ 
concerns, needs and QoL, as opposed to solely focusing on a disease-centered approach with 
mainly survival-related outcomes. The editorial of Ben-Arye and Samuels further indicates that 
there is a current unmet need to address the way patients view their disease; the actual cancer 
treatment process; the interaction with spouses, parents, children and other caregivers; and the 
barriers of communication with health care providers (Ben-Arye and Samuels, 2015). 
In an atempt to address the previously mentioned unmet needs of cancer patients, the 
MUHC has been instrumental in initiating a unique cancer nutrition rehabilitation program  and 
throughout the last  14 years, the program has evolved and underwent significant change with 
the  most recent  version  of the  program  centralized  within the  Division  of  Supportive  and 
Paliative Care at the MGH and MNUPAL. The program now known as CARE endeavors to help 
each  cancer  patient  maximize their  physical,  nutritional  and  cognitive functioning,  after the 
debilitating efects of the disease and its treatment. The goal of this program is to have patients 
take beter control of their lives by improving their functional status and QoL, through the help of 
an interdisciplinary team.   Using  a  personalized  approach  of information  delivery,  patients  wil 
be  educated regarding  symptom  control,  prescription  of  exercises,  suggestions for  behavioral 
modification, and psychological support by specificaly trained health care professionals. 
Patients  and their family  wil  be  empowered to improve their  QoL  and  performance  during 













2.0 Literature Review 
Table  2a  summarizes  certain  key features  of rehabilitation  programs taking  place in 
Europe and Australia. 
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The Italian integrative supportive care program of Vasile et al. is in an ambulatory room 
incorporated into an oncology unit. This particular team worked 6 days/week and saw planned 
and  unplanned  cancer  patients  with treatment complications. Interesting  conclusions from this 
study include:  only  5.5%  of  patients  were further  hospitalized,  10%  of  patients  would  need 
unscheduled hospital access for supportive care, and having an ambulatory for supportive care 
localized into the oncology unit encourages a more rapid admission of patients for management 
of symptoms and toxicities (Vasile et al., 2014). The 3+1 week multidisciplinary inpatient cancer 
rehabilitation  program that  Bertheussen  et  al.  studied  assessed its feasibility for  cancer 
survivors.  The  program included physical training, patient education and group sessions. The 
study  concluded that this  program  was  not  only feasible,  but the  patients’  symptoms  and 
functioning  stabilized  after rehabilitation (Bertheussen  et  al.,  2012).  The  goal  of the  8-week 
Australian CNRP was to manage the ACS with individualized interventions in nutrition, exercise, 
and symptom management. The staf consisted of a physician, dietitian and physical therapist. 
Moderate improvements  were found in  median  weight,  KPS  and  ESAS  scores,  strength  and 
endurance, and CRP levels (Glare et al., 2011). 
 
Table  2b  summarizes  certain  key features  of rehabilitation  programs taking  place in 






Table 2b. Texas cancer rehabilitation programs 
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Rhondali  et  al.  studied  an  outpatient  Supportive  Care  Clinic for  2  years.  The team 
consisted of physicians and registered nurses specialized in paliative care, pharmacists, 
nutritionists,  chaplains,  social  worker,  psychiatric  nurse-counselor  and  wound  care  nurse. 
Interestingly  enough,  more than  half  of the  cancer  patients  with  moderate to  severe  self-
reported  depression  significantly improved  after  one  visit (Rhondali  et  al.,  2014).  Shin  et  al. 
studied the  acute inpatient interdisciplinary rehabilitation  unit in the  MD  Anderson  Cancer 
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Center for  1  year.  This  unit  had the  main  goal  of  discharging  cancer  patients to their  home 
seting.  With the  help  of  a  physiatrist;  nurse  practitioner  and rehabilitation  nursing specialist; 
physical,  occupational  and  speech therapist;  nutritionist;  pharmacist;  case  manager  and 
chaplain, the  clinic  was  able to  successfuly  discharge  home  76%  of its  patients (Shin  et  al., 
2011). 
Table  2c  summarizes  certain  key features  of rehabilitation  programs taking  place in 
Ontario and Quebec. 
Table 2c. Ontario and Quebec cancer rehabilitation programs 
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Chasen  et  al.  studied the  8-week interprofessional  Paliative  Rehabilitation  Program in 
Otawa,  with the  main  goal  of improving  patient functioning.  The team  comprised  of  a 
physiotherapist,  occupational therapist,  social  worker,  dietitian,  nurse  and  physician.  Some 
improvement was shown in decreasing symptom burden and daily interference, and increasing 
nutritional, physical and functional status. Additionaly, normal CRP levels were shown to predict 
program completion (Chasen et al., 2013). In Montreal, Gagnon et al. studied a similar type of 
program for  3.75  years,  which  yielded  similar results.  That team  concluded that  an 
interdisciplinary  program  of that  nature  should  be  considered  as  a  standard  part  of  paliative 
care, as it shows some benefits for advanced cancer patients (Gagnon et al., 2013). Lastly, the 
8-week interdisciplinary Cancer Rehabilitation Service at the RVH studied by Eades et al. was 
also  quite  similar to the two  previous  programs.  The  head  and  neck  cancer  patients  had 
clinicaly meaningful improvements in symptom burden, distress, QoL and the 6MWT. However, 
there was no change in symptom interference with function. The study concluded that this type 
of interdisciplinary  program  can  be  of  benefit to the  head  and  neck  cancer  patients  after 
treatment, however a controled trial should be performed to beter evaluate its efects (Eades et 
al., 2013). 
The Jewish General Hospital’s Peter Brojde Lung Cancer Centre presented a novel and 
diverse way of interpreting rehabilitation by combining integrative oncology, traditional Chinese 
medicine  and the  discipline  of  nursing.  The  whole idea  behind this  program  was to provide 
patients  with the  opportunity  of  geting involved in  a  variety  of  holistic  activities,  under the 
supervision  of  a team  of  health  care  professionals  who  are familiar to the  patients.  Patients 
involved in this  program  had access to a family room, a conference room, a larger Qi Gong 
room for physiotherapy sessions, qi gong, yoga, patient and family support groups, and learning 
sessions on various topics such as nutrition, healthy lifestyles, Chinese herbs and supplements, 
meditation,  music,  and  art.  The idea  of  having this  program  within the  hospital  seting  was to 
ensure patient safety and program compliance. If these complementary therapy services were 
located elsewhere, perhaps, patients would be less inclined to atend (Grossman et al., 2012). 
Kasymjanova  et  al. from the Peter Brojde Lung Cancer Centre program, took a holistic 
approach to  aleviate  patient sequelae and were the first to  show that  acupuncture  might be 
efective at relieving certain symptoms in lung cancer patients. Patients who received 45-minute 
sessions of acupuncture, once or twice weekly for a minimum of 4 sessions, showed improved 
ESAS scores for pain and wel-being (Kasymjanova et al., 2013). 
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Cancer  survivors  of  al  ages, from  young  adolescents to  older  adults,  have  dificulty 
performing the same level of physical activity, as they once were able to complete. Murnane et 
al. were able to demonstrate that the adolescents and young adults unable to perform physical 
activity  guidelines showed  a  worse  QoL (Murnane  et  al.,  2015). In terms of the pediatric and 
older  adult  cancer  population,  evidence from  previous research  has  shown that there is  an 
association  between  physical  activity  and improved  QoL, health-related fitness  and  survival 
outcomes (Conn et al., 2006; Cramp & Daniel, 2008; Schmitz et al., 2005; Knols et al., 2005; 
Huang  &  Ness,  2011). In  addition,  when  exercise  was  prescribed  either throughout or after 
cancer treatment, it was shown to be an efective intervention, whereby, it ameliorated cardio-
respiratory fitness, treated side efects (e.g., fatigue) and enhanced QoL and psychological wel-
being for  adult  cancer  patients (Dimeo et al., 1999; Galvao & Newton, 2005; Jacobsen et al., 
2007; Hayes et al., 2009). For those reasons, interventions encouraging and educating physical 
activity and healthy lifestyle behaviors is of utmost importance to QoL of cancer survivors in the 
long-term (Murnane et al., 2015). 
Looking  at the Gudbergsson  et  al. review of a  multitude  of published randomized 
controled trials from  1990 to  2011  on  cancer rehabilitation, their main findings include that: 
program content and patient samples were not homogeneous; there were a scarce number of 
studies that use a combination of rehabilitative eforts to accommodate the many disabilities of 
patients; a lack of adequately described baseline disease and functional impairments; a lack of 
statistical power and large enough sample sizes to perform group comparisons; there were no 
determined long-term beneficial or unfavorable efects associated to interventions mostly due to 
lack of or brief FU duration; lack of atrition analyses and external validity issues (Gudbergsson 
et  al.,  2015). Recommendations from both Scot et al. and Gudbergsson  et  al. to researchers 
creating randomized controled trials for cancer rehabilitation programs, involve providing more 
systemic and specific details on the sampling, statistical power, atrition, and disease/treatment 
characteristics (e.g., time from  diagnosis to interventions,  cancer treatment received, and 
disease/treatment status during the intervention period) (Scot et al., 2013 & Gudbergsson et al., 
2015). Several conclusions derived from Gudbergsson’s review were that overal studies looking 
at cancer rehabilitation programs need to be: more methodologicaly detailed; multidimensional; 
under a stricter type of organization and systemic data colection; as wel as, evaluate and look 
more  closely  at  outcomes  concerning the  cancer  patient’s  actual  physical,  psychological  and 
social limitations  versus tending  mostly to  secondary  prevention, lifestyle  changes  and 
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supportive care (e.g., addressing risk factors for a future disease burden caused by the cancer 
and/or its treatment) (Gudbergsson et al., 2015). 
Silver et al. published a review looking at the management of paliative care programs, 
as  wel  as  assessing  physical function.  Research  has  shown that  paliative  care  has  only 
recently  been integrating  a  physical rehabilitation  component to their  programs (Silver  et  al., 
2015). Salakari et al. reviewed thirteen randomized controled trials published in 2009-2014, and 
found the folowing  significant improvements in  advanced  cancer  patients receiving  both 
physical rehabilitation  and  paliative  care:  physical  performance,  general  wel-being,  QOL, 
fatigue, general condition, mood, and coping with cancer (Salakari et al., 2015). Other studies 
suggest that  paliative  care  services  may lead to less  emergency  department  visits, 
rehabilitation  may  prevent  hospital-acquired  disability,  and  prehabilitation  may improve 
outcomes and decrease costs. The overal consensus is that more data needs to accumulated 
and  more randomized  controled trials  need to  be  published,  however, the  current information 
available to  us  suggest that rehabilitation  may  be recommended for  cancer  patients (Silver et 
al., 2015). 
Loh and Musa conducted a systemic review, also in 2015, concerning the rehabilitation 
of breast cancer patients after surgery. They concluded that the currently used programs have 
concentrated more on  performance  based  and/or  physical  components (e.g.,  physical 
impairments/  dysfunctions),  and  evidence  does  show that  exercise-focused  programs  helped 
breast cancer patients with shoulder mobility and lymphedema. On the other hand, the review 
demonstrated that those same programs displayed unconvincing improvements in non-physical 
sequelae (e.g., psychosocial, cognitive, occupational, and broader lifestyle performance factors) 
(Loh and Musa, 2015). 
In essence, a noteworthy number of patients afected by cancer and its treatments are in 
need  of improving their  physical, functional  and  QoL  status. In  order to  address these  crucial 
needs,  cancer rehabilitation  programs  have  been  developed to  help  deal  with the  patients’ 
symptom  burden, functional loss,  and physical  and  psychological  status.  The  majority  of 
rehabilitation programs used a combination of self-reported questionnaires and functional tests 
to assess the overal welbeing of the patient. Although these programs have reported marginal 
to  moderate levels  of  success in terms  of the  overal improvements in  a  mixed  patient 
population, what appears to be missing is a more personalized approach to patient assessment 
along with a systematic categorical intake system that places patients into assessment streams 
based upon disease severity. 
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3.0 History and Development of the CARE Program 
The first  4  years (2002-2006): In  2002, the  McGil  Cancer  Nutrition-Rehabilitation 
Service was established with the ambitious goals to care for cancer patients sufering from poor 
appetite,  malnutrition,  weight loss, fatigue  and loss  of function.  The team  behind this  program 
believed that nutritional counseling, together with an exercise program and dedicated symptom 
control,  would improve QoL and functioning in advanced cancer patients. It  was intended for 
early paliative care, for those with a possibly fatal cancer (Gagnon et al., 2013). The program 
was placed in the Division of Paliative Care and the Department of Oncology (McGil University 
and the  Sir  Mortimer  B.  Davis-JGH), and the Department of Medicine at the McGil University 
Health Centre (MUHC). Initialy, the Cancer Nutrition-Rehabilitation Service began operations in 
the Pulmonary Division of the Sir Mortimer B. Davis-JGH. The clinic operated 2 days/week with 
more focus  on  personalized  nutritional  counseling  and the  administration  of  nutritional 
supplements to combat the loss of appetite and weight.  After some development, it expanded 
and  moved to the  MUHC-MGH in  December  of  2003.  Subsequently, the  MUHC-MGH  clinic 
relocated to the  RVH,  and in  January  2006 launched the  new  Cancer  Nutrition-Rehabilitation 
Program (part of the Department of Oncology at the MUHC) (Jagoe & Chasen, 2007). 
The  next  6  years (2006-2012): The new clinic operated 1.5 days/week  with  a 
multidisciplinary team  consisting  of  an  oncologist/paliative  care  physician,  a  psychologist,  a 
nurse,  physiotherapist,  occupational therapist,  dietician  and  social  services  worker.  The 
treatment  plans from this  program  emphasized individualized physical rehabilitation to counter 
fatigue and loss of function, and psychological programs, in addition to nutrition. At this point in 
time,  patients  were  not  separated into  distinct rehabilitation  streams  based  upon  predicted 
survival, rather the  program  accepted  mostly  advanced  cancer  patients including those  with 
cachexia. Unfortunately, the program had relatively low patient enrolments and, in the opinion of 
the Oncology Mission, had minimal reported costs/benefits (Jagoe & Chasen, 2007). 
The last 4 years (2012-the  present): The program relocated back to the MGH in late 
2012 and at the present time, it is included within the Supportive and Paliative Care Service of 
the  MUHC  at the  MNUPAL location.  This last relocation  came  with  a new name (CARE 
Program) and the opportunity to revise, change and make the program more eficient with the 
hope of recruiting and benefiting more patients. The CARE currently operates 2 days/week and 
the team consists of a physician specialized in paliative care, a head registered pivot nurse, a 
physiotherapist,  an  occupational therapist,  and  a  dietician.  Each  of the  professionals meets 
each patient on an individual basis through a series of thirty-minute appointments (please refer 
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to Appendix A to visualize the CARE program schedule), which has been a core feature since 
the inception  of the  original  program in  2002.  No  definitive rehabilitation  pathways  have  been 
established yet for cancer patients. A novel and unique feature of the CARE program is the fact 
that  al the referred  patients  are  categorized into  one  of the folowing three  specific  program 
paths/ rehabilitation pathways to meet the various specialized and personalized needs of cancer 
patients  and  survivors:  1)  Restorative,  2)  Supportive,  and  3)  Cachexia.  The  cancer  patient’s 
disease status,  prognosis  and  needs determine their pathway assignment. The patient 
population with no signs of active disease and in need to return to their usual activities wil be 
assigned to the Restorative group; those with active disease, undergoing oncological treatments 
and in need of nutritional and functional reconditioning with a prognosis of 6 months or greater 
wil  be  assigned to the  Supportive  group;  and those  with  non-curative intent,  more  advanced 
disease and sufering from weight loss, anorexia and fatigue with a prognosis of greater than 3 
months  wil  be  assigned to the  Cachexia  group. Cancer  cachexia is  a  multi-factorial  wasting 
syndrome, which deals with a significant reduction in skeletal muscle mass, with or without the 
loss  of  adipose tissue, and is  often  associated  with loss  of  appetite  or  anorexia (Evans et al., 
2008). 
In addition to the initial and final program visits, another key and essential feature of this 
program  are the  planned  FU  visits that  each  professional  wil  have  with  each  patient. This 
important addition serves to more closely monitor, to provide timely feedback, and to beter treat 
the patients. The subjective measures chosen by the CARE team to evaluate the HRQoL of the 
patients enroled in the program include the folowing subjective outcomes: the abridged Patient-
Generated  Subjective  Global  Assessment (aPG-SGA),  Edmonton  Symptom  Assessment 
System (ESAS), Fatigue  Symptom Inventory (FSI), Distress Screening Tool (DST) and the 
Modified Community Healthy Activities Model Program for Seniors (m-CHAMPS). Each of those 
measures  were  chosen  by the CARE team members as a result of both literature 
recommendations  and their  experience to  be the  most  appropriate  assessing  malnutrition, 
frequently experienced symptoms, fatigue, distress and physical activity levels.  
A post-program evaluation is an essential step that unfortunately is often done poorly, or 
not  done  at  al.  As  of  January  2014 the CARE  program is oficialy ongoing, however, 
outstandingly  enough there  are  no  measures  of  efectiveness  with respect to subjective tests 
and  measures  performed  on  each  patient.  Therefore, this  study  wil retrospectively evaluate 
whether the  goals  of the interdisciplinary CARE  program  at the  MUHC  were  achieved  by 
assessing the subjective outcome measures of this program along, with other demographic and 
	  14	  
clinical  characteristics.  This wil provide clues on which patients may have benefited the most 
from participating in the program and determine whether the patient made HRQoL progress on 
the account of the program. If there is a significant improvement in the subjective tests, it comes 
with the  understanding that these  changes  may  be  varied  even  within  each  stream.  This is 
customary in clinical programs of this nature in part due to the complexity of the disease state. 
Another important part of this study wil identify if the classification of cancer patients within the 
three rehabilitation pathways is clinicaly meaningful. Ultimately, it is important to note that this is 
a preliminary study, to publish certain observed trends. 
The primary objective of this study is to evaluate the impact of the interdisciplinary CARE 
program on the cancer patients’ HRQoL, by monitoring their self-reported questionnaire scores. 
Another important  objective of this study is to determine if  patients referred to the three 
pathways were in fact diferent from a nutritional, functional and symptom profile perspective. 
Secondary  objectives involve  keeping track  of the  patient’s demographic  and  anthropometric 
information and blood biochemical profile. 
4.0 Research questions and hypotheses 
The research  questions  and  hypotheses  have  been  organized in  such  a  way  as to 
compare the dependent (e.g., aPG-SGA, ESAS, FSI, DST and m-CHAMPS) variable responses 
within (intra-group) and between (inter-group) each independent  variable (e.g.,  Restorative, 
Supportive and Cachexia). The intra-group comparisons wil determine if there are diferences in 
each  dependent  variable  within  each  stream  over time. The inter-group  comparisons  wil 
determine if there  are  pre-post  diferences in  each  dependent  variable  among the three 
rehabilitation  pathways.  The folowing  describes in  detail  each  of the research  questions  with 
their respective hypotheses. Based upon their current tumor types and staging, patients in the 
Restorative group are hypothesized to demonstrate significant improvements compared to the 
patients in the Supportive group. Folowing the same rationale, patients in the Supportive group 
are  hypothesized to  demonstrate  significant improvements  compared to the  patients in the 
Cachexia group.  
4.1 Intra-group comparisons  
Research  Question  1:  Wil patients within the Restorative, Supportive and Cachexia groups 
show significant improvements over time with respect to individual scores in the aPG-SGA and 
ESAS, and pre-post with respect to individual scores in the FSI, DST and m-CHAMPS?  
 Hypothesis  1.1:  Patients in the  Restorative  and  Supportive  group  wil  demonstrate 
significant improvements in individual scores on the aPG-SGA (decrease) and ESAS (decrease) 
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over time, and on the FSI (decrease), DST (decrease & fewer checked boxes) and m-CHAMPS 
(decrease in  sedentary  activity  & increase in light,  moderate  and  heavy  physical  activity)  pre-
post. 
 Hypothesis  1.2:  Patients in the  Cachexia  group  wil  demonstrate  maintained individual 
scores  on the aPG-SGA  and  ESAS  over time,  and on the  FSI (decrease),  DST (decrease  & 
fewer  checked  boxes)  and  m-CHAMPS (decrease in  sedentary  activity  & increase in light, 
moderate and heavy physical activity) pre-post. 
4.2 Inter-group comparisons 
Research  Question 2: At  baseline,  when  comparing the  aPG-SGA,  ESAS,  FSI,  DST  and  m-
CHAMPS questionnaire scores between each pairing of the rehabilitation programs (restorative 
vs.  supportive, restorative  vs.  cachexia  and  supportive  vs.  cachexia),  wil the findings in the 
restorative  group  be  greater than those  of the  supportive  group,  and  wil the  supportive  group 
have beter results than the cachexia group? 
 Hypothesis 2.1: At baseline, the patients in the Restorative group wil show a statisticaly 
higher HRQoL score compared to the Supportive group with regards to the scores of the aPG-
SGA (a lower score), ESAS (a lower score), FSI (a lower score), DST (a lower score & fewer 
checked  boxes)  and  m-CHAMPS (a lower  score in  sedentary  activity  & higher  score in light, 
moderate and heavy physical activity). 
 Hypothesis 2.2: At baseline, the patients in the Supportive group wil show a statisticaly 
higher HRQoL score compared to the Cachexia group with regards to the scores of the  aPG-
SGA (a lower score), ESAS (a lower score), FSI (a lower score), DST (a lower score & fewer 
checked  boxes)  and  m-CHAMPS (a lower  score in  sedentary  activity  & higher  score in light, 
moderate and heavy physical activity). 
Research  Question 3:  When  comparing the  aPG-SGA  and  ESAS  questionnaire scores over 
time;  and the FSI,  DST  and  m-CHAMPS pre-post, between each pairing of the rehabilitation 
programs (restorative vs. supportive, restorative vs. cachexia and supportive vs. cachexia), wil 
the findings in the restorative group be greater than those of the supportive group, and wil the 
supportive group have beter results than the cachexia group?  
 Hypothesis  3.1:  Patients in the  Restorative  group  wil  show  a  statisticaly  significant 
improvement compared to the Supportive group with regards to the scores of the aPG-SGA (a 
higher decrease) and ESAS (a higher decrease) over time; and of the FSI (a higher decrease), 
DST (a  higher  decrease  & fewer  checked  boxes)  and  m-CHAMPS (a  higher  decrease in 
sedentary activity & increase in light, moderate and heavy physical activity) pre-post. 
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 Hypothesis  3.2:  Patients in the  Supportive  group  wil  show  a  statisticaly  significant 
improvement  compared to the  Cachexia  group  with regards to the  scores  of the  aPG-SGA (a 
higher decrease) and ESAS (a higher decrease) over time; and for the FSI (a higher decrease), 
DST (a  higher  decrease  & fewer  checked  boxes)  and  m-CHAMPS (a  higher  decrease in 
sedentary activity & increase in light, moderate and heavy physical activity) pre-post. 
5.0 Methods 
5.1 Study Design 
This  study had an observational retrospective design with repeated measures of the 
health outcomes in each patient both within and between the three rehabilitation pathways. This 
particular  design  was used to evaluate each patient’s progress  within their pathway and if the 
patient’s outcomes difer between pathways. Although this research design does not randomize 
patients into  certain  groups  and  does  not have  a  control  group, it  was efective at ilustrating 
whether the subjective health-related outcomes in patients receiving various cancer treatments 
have  maintained, improved  or worsened. Patient outcomes were compared to their own 
baseline, and other health related outcomes were analyzed across the three diferent program 
streams. Please refer to Appendix B to understand how the cancer patients were separated into 
three distinct pathways. 
5.2 Study Setting and Sample 
 Patients  were primarily referred to this program by other professionals within the 
Supportive and Paliative Care Unit, that includes members of the Cancer Pain, Paliative Care, 
Cancer  Rehabilitation  and Cachexia, and Lymphedema Clinics. Any cancer specialists at the 
MUHC that  know  of the  program,  whether it  be  nurses,  oncologists,  surgeons,  or 
anesthesiologists,  must fil  out the  Cancer  Care  Mission’s  Supportive  Care  Program  Referral 
Form (please refer to Appendix C the view the referral form) that identifies potential patients to 
the program, and then fax it to the secretary. This program referral form serves as a basis for 
the telephone triages to be made by the pivot nurse. The combined information gained from the 
referral form and telephone triage is an initial atempt to beter understand the general status of 
the patient before the secretary books an appointment. The referral form does have a specific 
indicator/pre-screen item for cachectic patients by identifying weight loss. If there is no 
significant weight loss for the patient to be classified as cachectic, then they are classified into 
either the restorative  or  supportive  cancer rehabilitation  stream.  Restorative  patients  were  at 
one time  diagnosed  with  cancer,  but  have  undergone  curative therapy/surgical removal  of the 
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tumor mass or are presently in remission. If the patient is not classified as Restorative, then they 
wil likely be entered into the Supportive stream. 
 Consecutive outpatients referred to the CARE program of the Supportive Care Program 
of the Cancer Mission at the MUHC wil be considered for enrolment. The assessments wil be 
obtained at both the MGH Supportive and Paliative Care Unit and MNUPAL. For the purposes 
of this study, data wil be colected and analyzed from only new patients included in the CARE 
program between January 1st, 2014 and December 31st, 2014. 
5.3 Participants Inclusion and Exclusion Criteria 
 The restorative  and  supportive rehabilitation  programs  address  patient  concerns 
secondary to cancer and/or its treatment such as deconditioning, fatigue, weakness, nutritional 
and digestive problems or cognitive loss requiring an interdisciplinary approach. The restorative 
patients have been seen for post treatment evaluation by oncology and are at least one month 
of treatment;  whereas, the  supportive  patients  have  signs  of  active  disease,  with  or  without 
undergoing treatment.  The  cachexia  patient  population includes  patients  with inoperable, 
incurable,  metastatic  cancer  presenting  with  weight loss,  anorexia  and indicators  of  abnormal 
metabolism (anemia, high CRP, hypoalbuminemia, increased tumor markers). 
 This  study  wil include  as  subjects al patients admited to the CARE program.  The 
program has diferent inclusion and exclusion criteria for each rehabilitation pathway. Eligibility 
wil be ascertained according to the folowing criteria:  
General Inclusion Criteria (common to al three): 
1) Al new patients wil undergo at least one initial assessment 
2) Patients with at least one of the folowing three core assessments by the professional team: 
ESAS, aPG-SGA or hand grip strength. 
Specific Inclusion Criteria: 
Restorative pathway: 
1. Age ≥ 18 years; 
2. Had histologicaly confirmed diagnosis of cancer but no longer exhibits any clinical signs of 
active disease; 
3. At least one month of treatment 
Supportive pathway: 
1. Age ≥ 18 years; 
2.  Histologicaly  confirmed  diagnosis  of  advanced  cancer (stage II/IV  or  stage I  undergoing 
chemotherapy); 
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3. Life expectancy ≥ 6 months according to the estimation made by the physician; 
4. Evidence of active disease and may or may not be undergoing treatment  
Cachexia pathway: 
1. Age ≥ 18 years; 
2. Histologicaly confirmed diagnosis of advanced cancer (stage II/IV);  
3. Inoperable and incurable metastatic cancer 
4. Life expectancy ≥ 3 months according to the estimation made by the physician; no curative 
intent 
5. Evidence of active advanced disease and may or may not be undergoing treatment 
6. ECOG 1 or 2 
Exclusion criteria (common to al three): 
1. Impossibility for patients to fil in the questionnaires in English or French; 
2. Life expectancy < 3 months according to the estimation made by the physician 
5.4 Description of the Program 
5.4.1 Role of the Professionals 
The CARE program operates both at the MGH site, on the 8th floor of its Livingston Hal, 
and  at the  Vendome  site,  within the  MNUPAL (htp:/mnupal.mcgil.ca). Its team  consists  of  a 
physician  specialized in  paliative  care,  a  head registered  pivot  nurse,  a  physiotherapist,  an 
occupational therapist,  and  a  dietitian.  Each  professional  provided personalized 
recommendations for each patient. For example, the atending physician addressed issues that 
impacted upon optimal symptom control, the improvement of the nutritional and metabolic state, 
the review of medication intake, and the assessment of the eficacy of medication. In addition to 
the  coordination  and  support role  of the  nurse,  other responsibilities included clarifying the 
patient’s  understanding  of the  disease  and treatment; review  strategies for  symptom 
management and discussing psychological distress and sexuality issues. The physical therapist 
dealt with creating home strengthening programs to  optimize  and/or regain  muscle  mass  and 
strength;  cardio and  balance training;  addressed musculoskeletal issues, scar mobility, 
posture/pain-relieving  positions  and fal-prevention techniques.  The occupational therapist 
addressed management of cancer-related fatigue, self-care, safety and activities of daily living. 
The  main  concerns  of the  dietitian included: the  possible factors  promoting  weight 
loss/gain/maintenance;  oral  care (e.g.,  mucositis);  sensory  changes related to  nutrition (e.  g., 
taste changes); centraly-mediated changes (e.g., dysphagia, loss of appetite); using the dietary 
management  of  diabetes,  GI tract implications (e.g.,  nausea  and  vomiting,  diarrhea,  and 
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constipation);  and  complimentary therapy/alternative  medicine (e.g.,  homeopathy remedies). 
Please refer to Appendix D for the complete list of planned interventions. 
5.4.2 Program Goals 
The intervention  goals for  patients in the  Restorative  and  Supportive  groups included: 
optimizing physical, nutritional and functional status, minimizing impact of cognitive dysfunction 
in  daily living,  and  educating  and  empowering  patients to  make  healthy life  choices.  The 
intervention  goals for  patients in the  Cachexia  group included:  optimizing  nutritional  and 
functional  status, identifying  and  minimizing  metabolic  abnormalities  associated  with  cachexia, 
and informing and empowering the patient to act on their nutritional status.  
5.4.3 Program Schedule 
The  program  was scheduled at the Vendome site every Wednesday and at the MGH 
every  Friday from 08:15 to  15:45.  The  secretary retrieved the medical charts of every patient 
with a scheduled appointment for that day. From 08:15 to 09:00, the team of professionals and 
MNUPAL research assistants gathered for the case presentations of each patient. The patients 
were expected to arrive at the clinic for 08:30, at which time, height and weight measurements 
were taken by the secretary. Subsequently, the  patient  was led into their respective rooms, 
where they  were instructed to fil out the folowing series of  questionnaires:  aPG-SGA,  ESAS, 
FSI, DST and m-CHAMPS. Thereafter, one of the professionals met up with the patients. Each 
of the five professionals individualy met with each scheduled patient through a series of thirty-
minute intervals that ran from  09:00 to  11:30.  From  11:30 to  13:15 (and  after  15:45), the five 
professionals  met  altogether to review  and to  discuss the  personalized recommendations that 
were meant to provide the patient with the greatest amount of benefit. The same rotation is then 
applied to the patients scheduled in the afternoon. From 13:15 to 15:45, each professional saw 
each scheduled patient through the series of thirty-minute intervals and rotated from patient to 
patient. Idealy, five patients were seen by each of the five professionals in a two and a half-hour 
period.  
The return  visits from  patients in the restorative  and  supportive  cancer  groups  were 
meant to take place over a 2-4  month  period,  where the  subjective  HRQoL  measures were 
repeatedly taken. The return visits from patients in the cachexia group also repeatedly assessed 
the subjective HRQoL measures, although not necessarily throughout a period of 2-4 months. 
 Patients in the Cachexia group undergoing the interdisciplinary CARE model were given 
the  opportunity to receive additional assessments at MNUPAL. Upon arrival at the laboratory, 
patients had their height and weight measurements taken. Oxidative stress was then measured 
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by  performing the  FORT  and  FORD test (using the  Form  Plus  Calegari  CR3000  blood 
analyzer),  which determined the oxidative status of the patient, and the ability of the patient’s 
plasma antioxidants to reduce a preformed radical cation (Pavlatou et al., 2009), respectively. 
Afterwards, the  patient’s resting  metabolic rate was measured using COSMED k4b2 portable 
metabolic analyzer. Subsequently, bone mineral content and body composition were assessed 
by DXA (GE Lunar Prodigy Advance DXA). The patient’s quadriceps muscle performance (e.g., 
peak torque, work and power) was then measured through isokinetic testing using the BIODEX 
(Medic  Atlas  system  3).  Additional functional  measurements were obtained including Jamar 
hand grip strength and the gait speed. 
5.4.4 Data storage and retrieval 
The data colected from the medical chart includes several questionnaires completed by 
the patients before each visit and the various functional tests performed during their visit. The 
clinical  measurements  wil  be  studied through  an  evaluation  of the  patients’  electronic record, 
available  on  OACIS.  OACIS  gathers  diferent types of patient data into a single source where 
clinicians  may  access,  document  and  analyze  a  patient’s  profile to readily recognize  and  deal 
with  urgent  needs (Telus  Health,  2014).  Detailed  demographic information,  booking 
appointments and other such descriptive information wil be studied through an evaluation of the 
patients’  electronic record,  available  on  MédiVisit.  MédiVisit is  an  application that the  MUHC 
uses for the  management  of  appointments in the  clinic (MédiSolution  Ltée,  2014).  Al  data 
colected from the  medical  charts,  OACIS  and  MédiVisit  wil  subsequently  be  entered into  a 
database application entitled FileMaker Go through the use of iPads. 
6.0 Ethical Considerations 
The proposal was submited to the MUHC Research and Ethics Commitee for approval 
by the Director  of  Professional  Services. Once  approval  was granted, a retrospective chart 
review was completed for each patient from January 1st to December 31st 2014. Al data that 
was colected and used in analyzing the impact of this program was not linked to the individual 
results of patients included in the study. Any patient who did not conform to the inclusion criteria 
was not involved in the analysis. The treatment plan was not biased by the patient’s inability to 
conform to the inclusion criteria. 
7.0 Study measurements 
 Patient  demographics:  Demographic  and  anthropometric information  were colected  on 
al  patients recruited including  age,  sex,  cancer  diagnosis,  stage  and  evidence  of  metastasis, 
number  of  visits  per  professional,  number  of  visits  per  clinic,  pathway  patient  was  assigned 
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folowing the first visit, length  of the  program  per  patient and the  number  of  patients that  died 
while enroled in the program.  
 Biochemical profile: A blood biochemical profile was obtained folowing selected clinical 
measurements: CRP, albumin, hemoglobin, white blood cel count, neutrophil, lymphocyte and 
testosterone. 
 This  study utilized selected subjective measurements, such as the aPG-SGA,  ESAS, 
FSI, DST and m-CHAMPS at the patients’ initial and final clinic visit. At every FU appointment, 
the  patients  were only required to complete the aPG-SGA  and  ESAS  questionnaires.  Please 
refer to Appendix E for samples of each questionnaire. 
7.1 Questionnaires 
 Abridged  Patient-Generated  Subjective  Global  Assessment (aPG-SGA): This 
questionnaire is a practical modification of the original PG-SGA. Despite the fact that there is no 
gold  standard to  characterize  malnutrition,  clinicians  have  been  using  other tools  such  as the 
PG-SGA, which has been validated to determine the nutritional status of cancer patients (Tan et 
al., 2015). The PG-SGA has proven to efectively detect malnutrition and was developed for use 
in the cancer patient population (Otery,  2000  &  Bauer  et  al.,  2002  & Velasco  et  al.,  2011). It 
consists of a self-reported  questionnaire, in  addition to  a  physical  examination  and  metabolic 
abnormalities scoring completed by the physician (Vigano et al., 2014). The scored PG-SGA is 
a nutrition assessment tool that has been shown to identify malnutrition in inpatient (Bauer et al., 
2002) and outpatient oncology patients and may anticipate QoL changes (Isenring et al., 2003). 
The  abridged  version  of the  PG-SGA  consists  solely  of the  self-reported  questionnaire,  which 
evaluates  weight  history, food intake,  appetite,  and  performance  status (Vigano  et  al.,  2014). 
This  questionnaire  has  been  validated  as  a reliable  nutritional  screening tool to identify 
malnutrition for  cancer  patients in  an  outpatient (Gabrielson  et  al.,  2013  and  Stoyanof  et  al., 
2009)  seting  and there is  a  solid  correlation  between the  PG-SGA  and  aPG-SGA (r2=0.97) 
(Stoyanof  et  al.,  2009). Box 1 (sub-scale  1) of the questionnaire concerns weight and weight 
changes  with  a  maximum  score  of  5; box 2 (sub-scale  2) focuses  on food intake  with  a 
maximum score of 4; box 3 (sub-scale 3) scores symptom profiling with a maximum score of 24; 
and, box 4 (sub-scale  4) reports functional status  with  a  maximum  score  of  3 (Vigano  et  al., 
2014).  The scores from  each  of those  boxes/sub-scales are  added  up to  give a total score 
ranging from 0 (no malnutrition problems) to 36 (worst possible malnutrition problems) (Vigano 
et  al.,  2014). Patients  with  an  overal  score ranging from:  0 to  1  are recognized to have no 
particular nutritional problems and in no need of intervention; (Vigano  et  al.,  2014) 2 to 8, are 
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deemed as having increasing nutritional problems and may benefit from, but are not in critical 
need of, dietitian driven (or other clinical) interventions; (Vigano et al., 2014) and 9 to 36, have a 
critical need for improved symptom management and/or nutrition-intervention options (Vigano et 
al.,  2014). The  aPG-SGA  was  able to  discriminate  malnourished from  wel-nourished  patients 
with a sensitivity of 93.8% and a specificity of 77.6%, which is very similar to the PG-SGA (97% 
sensitivity, 86 % specificity) (Stoyanof et al., 2009 and Gabrielson et al., 2013). 
 Edmonton  Symptom  Assessment  System (ESAS): This  questionnaire is  a  commonly 
used tool to evaluate the severity of the nine most frequently experienced symptoms in cancer 
patients, using a scale ranging from 0 (absence of symptoms) to 10 (worst possible symptoms) 
(Aktas  et  al.,  2015;  Moro  et  al.,  2006; Dudgeon et al., 1999). The symptoms examined in this 
reliable tool include:  pain, tiredness,  nausea,  depression,  anxiety,  drowsiness,  appetite,  wel-
being, and shortness of breath, with a possible tenth symptom chosen by the patient (Bruera et 
al.,  1991;  Chang  et  al.,  2000;  Philip  et  al.,  1998). The  ESAS  was  deemed  a  valid tool,  by  a 
longitudinal cancer patient cohort study, by comparing it to the MSAS, FACT and KPS status. 
The  ESAS  had  a test-retest  validity  beter  at  2  days  versus  1  week; the  distress ESAS score 
had a greater correlation to the physical symptom/wel-being subscales of the FACT, MSAS and 
with  KPS; individual items  and  summary  scores revealed  good internal  consistency  and  were 
associated with their corresponding FACT and MSAS measures; and, lastly, the individual items 
between the three tools were wel correlated (Chang et al., 2000). 
Fatigue Symptom Inventory (FSI): This tool has 14 items and assesses several facets of 
fatigue,  such  as  perceived  severity, frequency,  and interference  with  daily functioning.  This 
questionnaire uses an 11-point scale, for each item, with the lower points signifying less acute 
fatigue problems. Items 1-13 wil be added up to calculate a globe score, whereas, question 14 
only  gives  qualitative  data (Shahid  et  al.,  2012). Initialy, the FSI was validated in the female 
breast cancer population (Hann et al., 1998 and Jacobsen et al., 1999) and then it was further 
validated in a mixed sex patient population with diferent types of cancers (Hann et al., 2000). 
The 1998 Hann study showed: convergent/divergent validity by comparing the FSI to the fatigue 
scale of the POMS-F and the SF-36 vitality subscale; construct validity by comparing between 
and within the three groups of women (e.g., those undergoing treatment for breast cancer; those 
who had completed treatment; and, lastly those with no history of cancer), along with measures 
of anxiety and depression. The seven items dealing with the interference of fatigue in daily living 
had a good internal consistency (α-coeficients=0.94 for the women undergoing treatment; 0.95 
for those who had completed treatment; and, 0.93 for those with no history of cancer). Test-
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retest reliability for the entire FSI among patients undergoing treatment varied from 0.35 to 0.75, 
and  was tested at three diferent times (Hann  et  al.,  1998). The 2000 Hann study further 
validated that the FSI was a reliable measure of fatigue in cancer patients, by showing: that the 
seven-item interference scale had good internal consistency (α-coeficients > 0.90); convergent 
validity by comparing it to an existing measure of fatigue; and, construct validity by comparing it 
to measures of life satisfaction and depression (Hann et al., 2000). 
Distress  Screening  Tool (DST): includes the distress thermometer which is a popular, 
acceptable  and rapid  screening tool  used to  evaluate the  psychological  distress  of  cancer 
patients (Stewart-Knight  et  al.,  2012). This tool comprises of three diferent  parts. In the first 
part, the  patients  are instructed to  circle the  number  on the thermometer that “best  describes 
how  much  distress they  have  been  experiencing in the  past  week including today” (NCCN 
Guidelines 2013). The second part is a list of problems divided into the five folowing sections: 
practical, family, emotional, spiritual and physical, and the patients are asked to “tick each item 
that  has  been  a  cause  of  distress for them  during the last  week including today” (NCCN 
Guidelines  2013). In the last part, the patients are asked to “select out of the items that they 
have ticked, the  3 items that  cause them the  most  concern” (NCCN  Guidelines  2013). The 
validity and reliability of the DST recommended by the NCCN was evaluated in Chinese cancer 
patients. In this study, the DT and problem checklist (Holand et al., 2000) was compared to the 
HADS and SCL-90.  The DT cutof score of 4 resulted in: an accuracy (or AUC)  of  0.80  with 
good sensitivity and specificity (0.80 and 0.70, respectively) when compared to HADS; and, an 
accuracy of 0.83 with a greater sensitivity and specificity (0.87 and 0.72, respectively) relative to 
SCL-90. Patients were then asked to fil out the DST at baseline and after 7-10 days, and the 
results  showed  an  acceptable test-retest reliability (r=0.800, P=0.000).  Overal, this  study 
indicates that DST has a reasonable accuracy and reliability to screen the severity of distress, 
as  wel  as,  problems  causing  distress in the tested  population (Tang  et  al.,  2011). In 2014, 
Chambers et al. tested the accuracy of DT by comparing it to the folowing three standardized 
scales: IES-R,  HADS  and  BSI-18.  When  compared to the IES-R, the  DT  demonstrated  high 
sensitivity (>85%)  and  good  accuracy (AUC  varying from  0.84 to  0.88),  at  al time  points.  At 
baseline, the  DT  showed  good  accuracy  compared to  both the  anxiety  and  depression 
subscales for  HADS (AUC=0.84  and  0.82, respectively),  however,  sensitivity  was  greatly 
reduced  after  12 months.  The  DT  displayed  a  high  validity for the  anxiety (AUC=0.90, 
sensitivity=90%)  and  depression (AUC=0.85,  sensitivity=74%)  subscales  of the  BSI-18.  This 
study concluded that the DT is a reliable tool to recognize distress, anxiety and depression in 
	  24	  
the prostate cancer population (Chambers et al., 2014). 
Modified Community Healthy Activities Model Program for Seniors (m-CHAMPS): The 
CHAMPS is a valid and reliable self-reported physical activity questionnaire used to assess the 
physical  activity  of  seniors.  This  questionnaire  evaluates the  occurrence  and  duration  of 
physical  activities  commonly  performed  by  older  adults  per  week (Stewart  et  al.,  2001). The 
modified CHAMPS is a useful and valid tool to measure change in levels of physical activity in a 
cancer population (Resnicow et al., 2003). Harada et al. assessed the measurement properties 
of  CHAMPS in  2001.  The  CHAMPS  was  compared to the  SF-36  measures  of  physical 
functioning,  general  health,  mental  health,  and  pain; BMI;  performance-based tests  of lower 
body functioning  and  endurance;  and, Mini-Logger  activity  monitor  data from  ankle  and  waist 
sensors. Data showed a fair validity (r2=0.48) and a good 2-week test-retest reliability (0.76) of 
the CHAMPS moderate activity (Harada et al., 2001). Stewart et al. also evaluated the reliability 
of the CHAMPS in 2001 and found that it had a good 6-month stability (ranging from r2= 0.58 to 
0.67) and modest construct validity correlations (ranging from r2=0.22 to 0.30) for the moderate-
intensity or greater activities, when compared to other physical function tests and self-reported 
QoL measures. This study  concluded that the  CHAMPS  might be suitable to assess the 
physical  activity levels  of  older  adults  undergoing interventions to increase physical activity 
(Stewart et al., 2001).  In 2006, Cyarto et al. evaluated the CHAMPS in older Australian adults 
by  comparing it to tests  of  physical  ability  and the  SF-12  measures  of  physical  and  mental 
health.  Results  showed  excelent  1-week test-retest reliability (ranging from  0.81 to  0.88) for 
moderate-intensity activity; and, significant validity correlations when compared to four physical 
performance tests (ranging from r2=0.19 to  0.32) (Cyarto  et  al.,  2006). In 2009, Giles and 
Marshal, also studied the validity of the CHAMPS in older Australian adults. Although, this study 
compared a mail-administered version of the CHAMPS questionnaire to an objective measure 
of  step  counts (using  a  pedometer).  The results  showed  good to  excelent  1 to  2-week test-
retest reliability for al the physical activity constructs (r2=0.70 to 0.89 sessions/week and r2=0.65 
to 0.75 for min/week); as wel as, good correlation coeficients between the weekly step counts 
and reported walking frequency and activity duration (r2= 0.57 and r2= 0.40, respectively). Good 
correlation coeficients were also noted between step counts and total reported physical activity 
frequency (r2= 0.52), however, when compared to total activity duration, the correlation was low 
(r2= 0.21).  Overal, the  data  demonstrated that, for the tested  population, the  mailed  self-
completed CHAMPS gave reliable and valid estimates of physical activity (Giles and Marshal, 
2009). 
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7.2 Blood Biochemistry  
C-reactive Protein: CRP is a widely used systemic biomarker for diagnosing acute and 
chronic inflammation,  promoted  by the  presence  of  a tumor (Gagnon  et  al.,  2013). Elevated 
serum CRP levels predict lower survival rates in patients with cancer (Srimuninnimit et al., 
2012).  
Albumin: It is the most abundant protein in human blood plasma, provides an estimation 
of visceral protein function and has a strong prognostic role in predicting cancer survival (Gupta 
& Lis, 2010). 
 Hemoglobin: It is the protein in red blood cels that carry oxygen, and low levels have 
shown to  negatively  afect  certain  cancer treatment  outcomes,  such  as  survival (Litlewood, 
2001). 
Neutrophils: are the most abundant white blood cel type, and they indicate systemic 
inflammation.  Significantly  high  neutrophil levels  are  associated  with  a  poor  prognosis 
(Tazzyman et al., 2009).  
Lymphocyte: is another type of white blood cel, which  confers immune response 
specificity.  Low levels  of lymphocytes  may  suggest  a  poor  prognosis for  diferent  stages  and 
types of tumors (Schueneman et al., 2013). 
Testosterone: monitoring bioavailable and total testosterone levels in our patients wil 
track  muscle  mass  changes.  Bioavailable testosterone  has  been  shown to  have  a  stronger 
association to  muscle  strength  compared to total testosterone (Roy  et  al.,  2002).  Low 
testosterone levels are correlated with an increased symptom burden, a lower QoL and a poor 
prognosis (Dev et al., 2014). 
8.0 Statistical analyses 
Baseline diferences by pathway were determined by a series of general linear models 
(proc glm). Mixed-model approach (PROC MIXED [repeated autoregressive]) was used for the 
analysis  of repeated measurements.  Fixed  efects included in the  model  were: rehabilitation 
pathway (restorative, supportive or cachexia), time and the product term of time and pathway. 
Covariates included in the  model  were:  sex,  age, whether the  patients  were  currently  on 
oncological treatment, days in program and number of FU visits. Al covariates were determined 
a  priori  based  on  established associations  with the  dependent  variables.  Al  baseline results 
dealing with the aPG-SGA, ESAS, FSI, DST and m-CHAMPS questionnaires were adjusted for 
the folowing covariates: age, sex and whether or not the patients were currently on oncological 
treatment. Results concerning the pre and post FSI, DST and m-CHAMPS questionnaire scores 
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were  adjusted for age,  sex,  on/of treatment  and  number  of  FU  visits  atended. Al over 
time/program  duration results  coming from the  aPG-SGA and  ESAS questionnaires  were 
adjusted for  age,  sex  and on/of treatment.  Mixed  models  were  used to  examine time 
diferences from pre-rehabilitation to post-rehabilitation in al rehabilitation pathways (cachexia, 
restorative and supportive), as wel as a function of pathway over multiple FU assessments (2 
week  blocks).  Al  analyses  were completed  using  SAS  9.3 (Cary,  NC,  USA),  with  significance 
set at p < 0.050. Occasional missing data are reflected in the degrees of freedom. The sample 
size of subjects was 115. 
8.1 Data manipulation and handling: 
Data truncation: In  order to  calculate  changes  over the  duration  of the  FUs,  data  was 
truncated into  2  week  windows  of  assesment.  To  achieve this, the  amount  of  days in the 
cancer rehabilitation program were calculated into weeks from entry into the program (baseline 
visit), and then categorized into 2 week blocks. Week 0 to week 2 was referred to as week block 
1, week 2 to week 4 was referred to as week block 2, week 4 to week 6 was referred to as week 
block  3  and  so  on.  Due to  a lack  of  participants  who  completed  FUs  beyond  24  weeks in the 
program (week block 12), truncation of the data beyond this point was computed, with the final 
FU beyond week 24 taken for any individual who had FUs after this time point. 
9.0 Results 
9.1 Patient demographics and clinical characteristics 
A total  of  115  MUHC  outpatients  with  cancer (mean  age  62.9  ±  13.4  y;  59%  male) 
participated in this study (Table 3a); where 24%, 34% and 42% of patients were referred to the 
restorative (n=28),  supportive (n=39)  and  cachexia (n=48) rehabilitation  pathway  streams, 
respectively. The most common primary cancer diagnoses were lung (30.4%), lower GI (12.2%) 
and breast (9.6%). Al restorative patients by definition are disease free and/or have a curative 
disease  status.  The  patients in the  other two  streams  had  a  history  of  advanced  cancer  as 
evidenced by the presence of either localy advanced (28% of supportive patients and 25% of 
cachectic patients) or metastatic (69% of supportive patients and 75% of cachectic patients) 
disease.  Patients  previously received  either  single treatment  of radiotherapy (11%),  single 
treatment of chemotherapy (36%) or their combination (37%) and are currently receiving either 
single treatment  of radiotherapy (2%),  single treatment  of  chemotherapy (47%)  or their 
combination (2%). The percentage of cancer patients not previously or currently receiving any 
oncological treatment is  16%  and 49%, respectively.  Throughout the  2014 time  period,  12 
patients passed away while in the CARE program. Overal, the average period of time that al 
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patients spent in the CARE is 75.8 (± 64.6) days, which included a baseline visit and an average 
of 2.6 (± 2.1) FU appointments. Referring to Table 3b, the age of patients in both the supportive 
(65.1  yrs  ±  11.4)  and cachexia (67.8  yrs  ±  11.4)  groups  proved to  be significantly  diferent 
(p=0.050) from the restorative (51.7  yrs  ±  13.0)  group.  The restorative  patients  atended 
significantly  more  FU visits (3.4  visits  ±  2.0)  compared to those in the  supportive (2.1  visits  ± 
2.0)  group.  As hypothesized,  and  due to their  advanced  disease  status  and increased 
debilitation, the cachectic patients had a statisticaly lower BMI (22.4 kg/m2 ± 5.1) compared to 
the two other groups. Another interesting finding concerns the white blood cel count, those of 
the cachectic patients were  significantly  higher (8.9*10⌃9/L  ±  5.0) than that  of the restorative 

























Table 3a. Baseline demographics and patient characteristics 
Variables Mean ± SD N 
Age (years) 62.9 ± 13.4 115 
BMI (kg/m2) 25.4 ± 6.4 114 
Albumin (g/L) 35.8 ± 5.7 76 
CRP (mg/L) 31.3 ± 45.9 31 
Hemoglobin (g/L)  113.5 ± 20.0 87 
WBC (109/L) 7.8 ± 4.2 87 
 % n 
Sex                    Male 






Cancer Diagnosis         Lung 
                       Lower GI 
                       Breast 
                       Hematology 
                       Liver Bioduct & Pancreas 
                       Gynecological 
                       Upper GI 
                       Urology 
                       Head and Neck 
                       Musculo-Skeletal System 
                       Neurology 
                       Skin 






























Previous Oncological Treatment  
                       Chemotherapy & Radiotherapy                       
                       Chemotherapy 
                       Radiotherapy 
                       
Concurrent Oncological Treatment  
                       Chemotherapy 
                       Chemotherapy & Radiotherapy                       
                       Radiotherapy 
































Table 3b. Baseline demographic and clinical patient characteristics divided by stream 
 Restorative Supportive Cachexia 
Variables Mean ± SE N Mean ± SE N Mean ± 
SE 
N 
Age (years) 51.7 ± 13.0  28 65.1 ± 11.4 
a 
39 67.8 ± 
11.4 a 
48 
Days in the program 97.8 ± 63.5 28 60.9 ± 55.5 39 75.1 ± 
69.5 
48 
Number of folow-up visits 
(excluding baseline) 
3.4 ± 2.0 28 2.1 ± 2.0 a 39 2.5 ± 
2.1 
48 
Weight at baseline visit (kg) 75.6 ± 18.5 28 75.3 ± 21.0 39 66.3 ± 
14.0 
47 
BMI (kg/m2) 27.1 ± 7.5 28 27.2 ± 7.1 39 22.4 ± 
5.1 a,b 
48 
Albumin (g/L) 39.3 ± 3.9 10 35.9 ± 5.4 30 34.8 ± 
6.1 
36 
CRP (mg/L) 38.8 ± 69.1 5 31.2 ± 45.2 8 29.2 ± 
41.7 
18 
Hemoglobin (g/L) 111.3 ± 
36.1 
13 112.8 ± 
14.5 
30 114.6 ± 
17.2 
44 
WBC (10^9/L) 5.9 ± 1.8 13 7.0 ± 3.1 30 8.9 ± 
5.0 a 
44 
 % n % n  % n 
Rehabilitation Pathway 
 
24 28 34 39 42 48 
Sex           Male 














             Curative 
             Localy advanced 

























Previous Oncological Treatment                    
Chemotherapy  
 
39.3 11 43.6 17 27.1 13 
Radiotherapy 
 
10.7 3 5.1 2 16.7 8 
Chemotherapy & Radiotherapy  
                                
50.0 14 33.3 13 31.1 12 
Concurrent Oncological Treatment  
Chemotherapy 
 
3.6 1 76.9 30 50.0 24 
Radiotherapy 
 
0.0 0 2.6 1 2.1 1 
Chemotherapy & Radiotherapy                        
                       
3.6 1 2.6 1 2.1 1 
a Significantly diferent (p ≤ 0.050) from Restorative; b Significantly diferent (p ≤ 0.050) 
from Supportive. 
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9.2 Differences between groups for initial aPG-SGA questionnaire scores 
The  details  of the  significant  main  efects of rehabilitation  pathway for four aPG-SGA 
questionnaire dependent  variables,  at  baseline,  wil folow.  Firstly, there  was  a  main  efect  of 
pathway for current  weight (F [2, 113]  =  4.38;  p  =  0.015),  however the  posthoc tests  did  not 
reveal specific group diferences*. Secondly, there was a main efect of pathway for weight loss 
history, which takes into  account the  weight loss from  one  month  ago if  available, and if not, 
then weight loss from six months ago is used, and that of the past two weeks (F [2, 113] = 7.39; 
p  =  0.001).  Post-hoc analyses (Tables  3c,  3n)  disclosed  significant  diferences (p ≤  0.050) 
between  both the restorative and  cachexia,  and  supportive  and  cachexia  groups.  Thirdly, the 
performance status variable, which considers the activities and function performed over the past 
month, also had a main efect of pathway (F [2,  113]  =  7.47;  p  =  0.001),  with  posthoc tests 
(Tables  3c,  3n)  demonstrating significant  diferences (p ≤  0.050)  between the restorative  and 
cachexia groups. Lastly, there was an efect of pathway for the total score variable (F [2, 113] = 
4.68; p=0.011), with the posthoc tests (Tables 3c, 3n) showing significant diferences (p ≤ 0.050) 
between the restorative and cachexia groups. Referring to Tables 3c and 3n, the cachexia (1.7 
±  1.6)  group reported  a worse  weight loss  score  compared to the restorative (0.6  ±  0.9)  and 
supportive (0.6  ±  1.1) groups; the restorative (1.2  ±  0.8)  patients reported  a  higher level  of 
physical  activity  and function  compared to the  cachexia (1.8  ±  1.0) patients;  and lastly, the 
cachectic (10.6 ± 5.6) patients reported greater overal malnutrition/total score compared to the 
restorative (6.2  ± 5.2) patients.  There  was  no  significant  main  efect  of pathway for the other 
aPG-SGA variables (p’s > 0.050). These analyses were adjusted for covariates. 
9.3 Differences between groups for initial ESAS questionnaire scores 
There was a significant main efect of pathway for the folowing two ESAS questionnaire 
dependent variables, at baseline: appetite (F [2, 113] = 7.74; p=0.001), where the posthoc tests 
(Tables 3c, 3o) showed significant diferences (p ≤0.050) between the restorative and cachexia 
groups; and fatigue (F [2, 113] = 3.16; p=0.047), here the posthoc tests (Table 3o) did not reveal 
specific group diferences*. The cachectic (4.9 ± 3.1) patients reported a worse appetite score 
compared to the restorative (2.5  ±  2.4)  patients  at their initial  clinic  visit (Tables  3c,  3o).  At 
baseline, there were no significant main efects of pathway for the other ESAS variables (p’s > 
0.050). These analyses were adjusted for covariates. 
9.4 Differences between groups for initial FSI questionnaire scores 
At baseline, there were no significant main efects of pathway for al fourteen variables 
linked to the FSI questionnaire. These analyses were adjusted for covariates. 
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9.5 Differences between groups for initial DST questionnaire score 
There is a significant main efect of pathway for sleep (F [2, 113] = 3.60; p=0.031) and 
weight (F [2,  113]  =  4.12;  p=0.019)  at  baseline,  where  posthoc  analyses (Tables  3c,  3p) 
exposed diferences (p ≤ 0.050) between the restorative and cachexia groups. Also, there was 
an efect of pathway for worrying about friends/family (F [2, 113] = 4.34; p = 0.015) where the 
posthocs (Tables 3c, 3p) displayed diferences (p ≤ 0.050) between the supportive and cachexia 
groups. Tables 3c and 3p show that there appear to be more restorative patients (67.9% ± 47.6) 
reporting feeling distressed with their quality and/or quantity of sleep compared to the cachectic 
patients (38.3% ± 49.1); more cachectic patients (63.8% ± 48.6) had a feeling of distress with 
their  body  weight  compared to the restorative  patients (35.7% ±  48.8);  and lastly,  more 
supportive  patients (53.8% ±  50.5) reported feeling  distressed for  worrying  about their family 
and/or friends  compared to the cachectic patients (27.7% ±  45.2).  There  were  no  significant 
main efects of pathway for the other twenty-three variables linked to the DST. These analyses 
were adjusted for covariates. 
9.6 Differences between groups for initial m-CHAMPS questionnaire scores 
At baseline, there were no significant main efects of pathway for the folowing four 
variables linked to the  m-CHAMPS:  hours  engaged in  sedentary, light,  moderate  and  heavy 

























Table 3c. aPG-SGA baseline diferences between groups 
 
















0.6 ± 0.9 
 
 
0.6 ± 1.1 
 
 






0.4 – 1.9 
0.4 – 1.8 
Food Intake  
 
0.8 ± 1.0 
 
0.7 ± 0.8 
 











3.6 ± 4.0 
 
5.5 ± 5.0 
 
















0.1 – 1.2 
Total Score  
6.2 ± 5.2 
 
8.3 ± 6.5 
 





1.1 – 7.8 
aPG-SGA scores range from: 
0 (no weight loss) to 5 (worse weight loss) for Weight Loss History 
                        
0 (no decrease in food intake) to 4 (worse decrease in food intake) for Food Intake 
                        
0 (no problems eating) to 24 (worse appetite) for Nutritional Impact Factors 
                        
0 (normal with no limitations) to 3 (worse performance) for Performance Status 
                        
0 (no malnutrition) to 36 (worst overal malnutrition status) for Total Score 
 
Values are Adjusted Means ± SD; n= 28 (Restorative); n=39 (Supportive); n= 47 (Cachexia) 
a Significantly diferent (p ≤ 0.050) from the Restorative group; b Significantly diferent (p ≤ 0.050) 













Table 3d. Baseline ESAS values for each variable among groups 
 
 Restorative Supportive Cachexia  







Anxiety 2.8 ± 2.8 2.6 ± 2.7 2.7 ± 2.6   
Appetite  
2.5 ± 2.4 
 
4.0 ± 3.0 
 




0.8 – 4.1 
Depression 2.5 ± 2.9 1.5 ± 2.1 2.0 ± 2.3   
Drowsiness 2.0 ± 2.5 3.5 ± 2.9 3.4 ± 3.1   
Fatigue 4.3 ± 2.4 5.5 ± 2.8 5.1 ± 2.5   
Nausea  
1.2 ± 2.2 
 
2.5 ± 3.4 
 





Pain 3.2 ± 2.5 3.8 ± 2.7 3.3 ± 2.7   
Shortness 
of Breath 
2.7 ± 2.7 3.4 ± 3.0 3.6 ± 3.2   
Wel-Being 4.4 ± 2.5 4.2 ± 2.6 5.1 ± 2.4   
 
ESAS scores range from 0 (best) to 10 (worst). 
 
Values are Adjusted Means ± SD; n= 28 (Restorative); n=39 (Supportive); n= 47 (Cachexia)  




Table 3e. DST score diferences at baseline visit between groups  
 
 Restorative Supportive Cachexia    












67.9 ± 47.6 
 
56.4 ± 50.2 
 









35.7 ± 48.8 
 





35.7 ± 48.8 53.8 ± 50.5 27.7 ± 45.2 b 26.2 1.8 – 5.1 114 
 
DST values are Adjusted Means (%) ± SD; where the percentage of subjects that are feeling 
distressed about the variable in question ranges from 0% to 100% 
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a Significantly diferent (p ≤ 0.050) from the Restorative group; b Significantly diferent (p ≤ 0.050) 
from the Supportive group. 
 
9.7 PRE/POST differences in FSI, DST and m-CHAMPS 
There were no significant (p ≤ 0.050) interactions between pathway and time (pre/post 
program) for any of the fourteen previously named variables linked to the FSI (Tables 3d-3g, 3q-
3nn). However, two FSI variables showed significant time efects, namely, least fatigue (F [2, 1] 
=  11.86;  p=0.006)  and  current fatigue (F [2,  1] = 11.30; p=0.006). The restorative patients 
experienced  a trend  decrease (p=0.055) in the level  of fatigue  on the  day  where they felt the 
least fatigued during the past week, it reduced from 2.8 ± 0.5 to 0.9 ± 0.7 post-program (Tables 
3d,  3e). The restorative patients also reported a significant decrease (p=0.050) in the level of 
fatigue experienced while filing out the questionnaire post-program, it declined from 3.4 ± 0.6 to 
2.0  ±  0.7 (Tables 3f, 3g). The  only  patients  with  DST  significant  changes from  pre to  post 
program  belonged to the cachexia  group,  with  a  diference in feeling  distressed for  practicaly 
geting to and from appointments (p=0.040) and a significant interaction between pathway and 
time of F [2, 1] = 9.38; p=0.008 (Tables 3h, 3i). Before the cachexia group started the program, 
17.5% ±  6.8 of the patients felt  distressed  going to  or from  appointments,  and folowing the 
program,  113.0% ±  25.2 of them  were  distressed (Table  3i). There  were  no  significant (p ≤ 
0.050) interactions between pathway and time for any of the other of the twenty-five variables 
linked to the  DST (Tables 3oo-3hhhh). There  were  no  significant (p ≤  0.050) interactions 
between pathway and time for any of the four perceived activity levels of intensity linked to the 
m-CHAMPS (Tables 3ii-3pppp). Al these analyses were adjusted for covariates. 
 
Table 3f. Fixed Efects Table of FSI Variable Least Fatigued PRE/POST Program 
 
Type 3 Tests of Fixed Effects Least Fatigued  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 97 0.67 0.516 
Time 1 11 11.86 0.006 
Pathway * Time 2 11 0.04 0.965 
Age 1 97 0.36 0.549 
Sex 1 97 0.20 0.659 
On Treatment 1 97 3.01 0.086 
Number of FUs 1 97 0.47 0.494 
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Adjusted Mean ± SE 
(Scores range from 0 = 
not at al fatigued ; 10 = 
as fatigued as I can be) 
 




PRE & POST 
Program FSI 
questionnaire 
Restorative 0 2.8 ± 0.5 23 
Restorative 1 0.9 ± 0.7 9 
Supportive 0 3.6 ± 0.4 35 
Supportive 1 1.8 ± 0.9 4 
Cachexia 0 3.6 ± 0.3 44 




Table 3h. Fixed Efects Table of FSI Variable Current fatigue PRE/POST Program 
 
Type 3 Tests of Fixed Effects Current fatigue  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 97 0.99 0.376 
Time 1 11 11.30 0.006 
Pathway * Time 2 11 0.09 0.917 
Age 1 97 1.08 0.302 
Sex 1 97 1.46 0.231 
On Treatment 1 97 1.12 0.294 















Adjusted Mean ± SE 
(Scores range from 0 = 
not at al fatigued ; 10 = 
as fatigued as I can be) 
 




PRE & POST 
Program FSI 
questionnaire 
Restorative 0 3.4 ± 0.6 23 
Restorative 1 2.0 ± 0.7 9 
Supportive 0 4.5 ± 0.5 36 
Supportive 1 3.3 ± 0.7 4 
Cachexia 0 4.4 ± 0.4 44 




Table 3j. Fixed Efects Table of DST Variable Getting to and from appointments PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Getting to and from appointments 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 3.57 0.032 
Time 1 8 1.69 0.230 
Pathway * Time 2 8 9.38 0.008 
Age 1 102 0.00 0.965 
Sex 1 102 0.14 0.709 
On Treatment 1 102 0.01 0.927 















Adjusted Mean (%) ± SE 
(percentage of patients 
feeling distressed) 
 





PRE & POST 
Program DST 
questionnaire 
Restorative 0 28.9 ± 10.8 25 
Restorative 1 15.3 ± 16.8 6 
Supportive 0 40.4 ± 7.9 38 
Supportive 1 5.0 ± 20.7 3 
Cachexia 0 17.5 ± 6.8 46 
Cachexia 1 113.0 ± 25.2 2 
 
9.8 aPG-SGA over time 
There  were  no  significant diferences/interactions for the total aPG-SGA malnutrition 
score among and within groups (rehabilitation pathways) over the 12 x 2-week block intervals of 
time (Tables 3j, 3k). However, there  was  a trend  main  efect  of  pathway (F [2,  1]  =  2.99; 
p=0.053) and a significant main time efect (F [2, 1] = 7.10; p=0.009) of the total score (Table 3j) 
for al patients. These analyses were adjusted for covariates. 
 
Table 3l. Fixed Efects Table of aPG-SGA variable Total Score over 12 two-week intervals 
 
Random Trend Model Type 3 Tests of Fixed Effects for Total Score 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 180 2.99 0.053 
2 Week Block Time Intervals 1 93 7.10 0.009 
Pathway * 2 Week Block Time Intervals 2 180 0.17 0.841 
Age 1 180 1.51 0.221 
Sex 1 180 1.59 0.209 






























2-Week Block Time Intervals 





9.9 ESAS over time 
 
None of the ESAS variables had a statisticaly significant interaction among and within 
groups over the 12 x 2-week block intervals of time (Tables 3l, 3m, 3qqqq-3fff). However, the 
appetite score did have a significant main efect of pathway (F [2, 1] = 10.43; p<0.0001) and a 
trend main efect of time (F [2, 1] = 3.46; p=0.067) for al patients (Table 3l). 
 
Table 3m. Fixed Efects Table of ESAS variable Appetite over 12 two-week intervals 
 
Random Trend Model Type 3 Tests of Fixed Effects for Appetite 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 10.43 <0.0001 
2 Week Block Time Intervals 1 93 3.46 0.067 
Pathway * 2 Week Block Time Intervals 2 179 0.47 0.629 
Age 1 179 1.04 0.310 
Sex 1 179 0.01 0.943 



















Figure 3. Plot of ESAS appetite score over time 













2-Week Block Time Intervals 





Besides the previously mentioned linear trend in time for the ESAS appetite score, there 
weren’t any other significant and/or consistent statistical trend of change among and within the 
three groups over the 12 x 2-week block intervals for the other ESAS variables. These changes 
are varied even within each stream, which is customary in clinical programs of this nature in part 
due to the complexity of the disease state. Another point to consider is the fact that each block 
interval of time includes a diferent subset of patients, therefore, any observed change doesn’t 
necessarily represent patient improvement. 
Please refer to Appendix F for al other tables and figures (plots) that weren’t put in the main text 
of the results section. 
10.0 Discussion 
 The  great  majority  of patients  afected  by  cancer and its treatments are in desperate 
need  of improving their  physical, functional  and  QoL  status. To  address these  needs,  cancer 
rehabilitation  programs  have  been  developed to  help  deal  with the  patients’  symptom  burden, 
functional loss,  and physical and psychological status. From the literature,  a  great deal of 
rehabilitation  program  assessments use a combination of self-reported  questionnaires  and 
functional tests to  assess the  overal  welbeing  of the  patient.  Generaly  speaking,  previous 
programs  have reported  marginal to  moderate levels  of  success in terms  of the  overal 
improvements in a mixed patient population. Recognized strengths from these programs include 
a fixed program duration (e.g., 10-12 weeks), and a pre-defined start and end visit date, which 
tends to encourage greater program completion. A major weakness of current programs is the 
lack of FU visits between program initiation and completion. Therefore, an important addition to 
programs would be to have patients come in for FU appointments to more closely monitor and 
beter treat them. However, what appears to be missing in the literature is a more personalized 
approach to patient assessment along with a systematic categorical intake system that places 
patients into  assessment  pathways  based  upon  disease  severity,  which is  exactly  what the 
MUHC’s CARE program does. Al patients referred to the CARE program are categorized into 
one  of the folowing three  specific  program rehabilitation  pathways to  meet the  various 
specialized and personalized needs of cancer patients and survivors: 1) Restorative, no signs of 
active disease and in need to return to their usual (work) activities; 2) Supportive, have active 
disease and are undergoing oncological treatments who are in need of nutritional and functional 
reconditioning;  and  3)  Cachexia, those  with  non-curative intent,  more  advanced  disease  and 
sufering from weight loss, anorexia and fatigue. 
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10.1 Baseline Comparisons 
 The  diferences  of  self-reported  questionnaire  scores  between  groups revealed  some 
significant and relevant variation between groups, further demonstrating that dividing the cancer 
patients in  diferent rehabilitation  pathways  might  be  clinicaly  meaningful,  at  baseline.  The 
restorative  and  cachexia  patients  had  significantly  diferent  BMI,  WBC,  weight loss  histories, 
performance  statuses, total  malnutrition  scores,  appetite,  and feelings  of  distress  concerning 
sleep and weight. Whereas, the supportive and cachexia patients portrayed diferences in BMI, 
weight loss history, and feelings of distress towards worrying about their friends/family. On the 
other  hand,  none  of the  variables  were  significantly  diferent  between the restorative  and 
supportive  pathways.  The  most baseline diferences in self-reported  questionnaires  and  other 
variables were  observed  between the restorative  and  cachexia  pathways  because,  clinicaly, 
those two types of patients are the most diferent. At baseline, the characterization of the three 
rehabilitation pathways seems to make sense. Clinicaly, the patients seem diferent at baseline, 
which favors the  argument that  patients  are in  need  of  diferent types  of rehabilitation 
interventions. 
10.2 Pre-post Program Comparisons  
This  preliminary  data  did  not  capture  much relevant  and  significant  changes  pre-post 
program, mainly due to the smal number of patients completing the post-program FSI, DST and 
m-CHAMPS  questionnaires and a lack of power. However, from the post-program  FSI 
questionnaires that  were filed  out, the restorative  patients reported  a trend  of lower levels  of 
fatigue, both, at the time the questionnaire was being completed (3.4 ± 0.6 to 2.0 ± 0.7) and the 
day, during the past week, where the patient felt the least fatigued (from 2.8 ± 0.5 to 0.9 ± 0.7). 
Although, being based upon nine patients, this is not clinicaly relevant. The DST saw a rise in 
the number of cachectic patients, from 17.5% ± 6.8 to 13.0% ± 25.2, feeling distressed geting 
to  and from  appointments,  however,  being  based upon only two patients, it isn’t a meaningful 
diference. The self-reported hours of physical activity (the occurrence and duration of physical 
activities  commonly  performed  per  week) did not significantly increase  or  decrease  post-
program for any of the patients. Also,  perhaps the  patients  are  more  similar than  we 
hypothesized, the groups filing out the questionnaires might not be as diferent as we taught.                                                                     
10.3 Program Duration Comparisons 
The  study  did report a  couple  of progress trends for the patients, as measured by the 
aPG-SGA  and  ESAS  questionnaires,  on the account of the program. The fixed efects  of the 
random trend  model did  not  show  any  significant interaction  of  pathway  over time,  however, 
	  43	  
there was a significant main efect of time for the aPG-SGA total malnutrition score and a trend 
main  efect  of time for the ESAS appetite score. Meaning that,  colectively,  patients in the 
program  did report  a  diference  over time  with respective to the two  previously  mentioned 
variables. The linear random trend efects in Figures 2 and 3 reflect the development of each 
group across time. These diferences are trends of progress, where Figure 2 displays a trend of 
lower total malnutrition score for al patients over time; and, Figure 3 shows a trend of appetite 
status improvement for  al  patients over time. Perhaps the patients started to take the  advice 
from the dietitan to modify their behavior for a healthier eating lifestyle, which may explain why 
progress trends were solely observed for the malnutrition and appetite status scores. 
 There  weren’t  any  other significant  and  clinicaly relevant  changes  or  program  efect 
when looking at the diferent questionnaire scores for the patients in the restorative, supportive 
and cachexia rehabilitation pathways over the 12 x 2-week block intervals of time. Rather, the 
observed trend for  al the  other  variables  was stable HRQoL questionnaire scores  across al 
three types of patients throughout the duration of the program, which is a positive finding for the 
cachexia  patients,  whose  health is rapidly  debilitating  due to rapid  decreases in  muscle  mass 
and fat,  poor functional  outcomes and becoming weaker,  as time  progresses. The  cachexia 
group experienced a stable HRQoL, according to the scores colected, as opposed to the two 
other groups. This may be more of a comment on the study’s experimental approach rather than 
the actual health of the patients. In general, the cachexia patients tend to be folowed up with 
more  closely  by the team  compared to the restorative  and  supportive  groups,  due to their 
debilitating prognosis. More data points and less missing data (because more atention was put 
on these patients) may have resulted in establishing a beter relationship between the variables 
inquestion.                                                                      
 Stable  self-reported HRQoL scores mean that the patients perceived that they did  not 
get worse while going through the CARE program. While the patients seem to not have made 
much  progress  while they  were  seeing the interdisciplinary team, they  didn’t  get  worse  either 
(e.g. a decline in HRQoL). Both the restorative and supportive patients definitely need help from 
rehabilitative  services to get them back on their feet.  Perhaps,  a  more  prominent  physical 
therapy and structured exercise component would beter reinforce an increase in strength and 
HRQoL. Inconsistent and incomplete colection of questionnaire scores, and the lack of 
structured and timely FU appointments (if any were scheduled at al, some patients were lost to 
FU) might  have afected the  analysis  of results  and  might  also  explain  why  not  much 
improvement was seen for the restorative and supportive patients. 
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The  only  hypotheses that  proved to  be true  were: 1) At  baseline, the  patients in the 
Restorative  group  showed a statisticaly significant improvement compared to the Cachexia 
group  with regards to some of the individual scores of the aPG-SGA,  ESAS and DST;  2) At 
baseline, the  patients in the Supportive group showed a statisticaly significant improvement 
compared to the Cachexia group with regards to one of the individual scores of the aPG-SGA 
and DST; and 3) Over folow-up visits, there was a trend of progress/improvement for the aPG-
SGA total malnutrition score and for the ESAS appetite status for al patients.  
 In theory, improvement in the HRQoL measures might have relieved symptom burden 
and  ameliorated  psychological  status,  more  so,  giving restorative  patients the  confidence  and 
support to return to  work  or their  usual  activities  and  possibly  alowing the  supportive  patients 
more comfortable daily living, although, this was not reflective in our results. 
 At  baseline, the  patients  are  classified into  diferent  categories  with  quite rigid  clinical 
criteria, which make sense, in the point of view of patient health status and prognosis, however, 
statisticaly (from the results we gathered over time) it doesn’t make sense. As time progresses, 
there was no HRQoL score variation between the groups. The supportive patients seem to be 
more homogenous in their responses, therefore, they seem to share the same outcomes. The 
homogeneity of supportive patients means losing their clinical identity. As time progresses, the 
disease status of the supportive (as wel as the patients from the other two groups) patients may 
evolve  over time.  Even though, they  were  classified,  at  baseline,  as  supportive, it  does  not 
necessarily mean that their clinical prognosis stayed, by definition, “supportive” throughout their 
involvement with the CARE program. With the supportive group, there might a mix of patients 
with symptoms similar to those in the restorative and cachexia groups. Therefore, they did not 
show  any  diferences perhaps because their  self-reported  HRQoL  outcomes  measures  are  a 
mix of restorative and cachectic patient symptoms. Also, the fact that some supportive patients 
were receiving systemic treatment and/or radiotherapy while participating in the CARE program 
might have afected the self-reported outcome measures. Certain HRQoL measures may have 
improved or worsened at any given visit, not necessarily due to their involvement in the CARE 
program, but rather due to benefits or side efects from their cancer treatment.  
Overal, the  patients  enroled in the CARE  program have not demonstrated significant 
improvements in  subjective HRQoL outcomes,  besides total  malnutrition  and  appetite  status, 
quite possibly due to lack of FUs and/or capturing FU data, and, possibly, the homogeneity of 
patients  between  groups.  If data  colection folowed its  proper  course,  and  every  patient 
completed the required questionnaires during every visit with the CARE program, the analyzed 
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data would have been more representative. Another issue concerns the irregular and 
sometimes long gaps of time between FU appointments, which realisticaly can be tough to work 
around simply because of the number of waitlisted patients. Statisticaly speaking, it isn’t easy to 
analyze clinical and personalized interventions. A more structured program where every patient 
has a fixed number of appointments might also be beneficial for program and data completion. 
The general goal of this program was to have patients take beter control of their lives by 
improving their functional status and QoL, through the help of an interdisciplinary team. Using a 
personalized  approach  of information  delivery,  patients  were  educated regarding  symptom 
control,  prescription  of  exercises,  suggestions for  behavioral  modification,  and  psychological 
support by specificaly trained health care professionals. Solely, looking at the scores from those 
five  selected  subjective  questionnaires, in addition to malnutrition and appetite status, the 
patients did not show any other meaningful trends of improvement in HRQoL. There is a great 
need for  personalized  and  more targeted interventions to  achieve  or  maintain  optimal 
performance and QoL in cancer survivors with diferent disease and treatment characteristics.                                 
10.4 Limitations of the Study 
 There  are  many  possible limitations that this research  project  may  have faced.  Those 
limitations that had the greatest potential impact on the quality of the findings and the ability to 
efectively  answer the research  questions  and/or  hypotheses  are  self-reported  outcome 
measures, limited external validity, lack of control group and retrospective design.  
 The  HRQoL  data  was  evaluated  using  subjective  and  patient-reported  assessments, 
which may have problems with honesty, accuracy of assessing ourselves, understanding, rating 
scales, response  bias, recal  bias, social  desirability  bias  and over-estimating  HRQoL (NICE 
Clinical Guidelines, 2009).  
 The study subjects received personalized interventions specific to their individual needs 
and goals, and therefore, interventions were not uniform. Individualized programs are the norm 
in  clinical  practice,  and  such  programs  are likely to  be  patient-centered rather than  uniform, 
which is  exactly  what  we  want in  a  cancer rehabilitation  program. However, statisticaly 
speaking,  when interventions  are  not  uniform, the results  are  particularly susceptible to bias, 
even though, clinicaly it is a strength.  
 Our findings are based on a relatively smal patient sample in a specific hospital seting, 
one centre only, therefore the generalizability to a larger population is limited. The conclusions 
from this study cannot be generalized to al cancer patients. The patient subject sample was not 
representative of al cancer patients, it only reflected the patients referred to the CARE program 
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from the MUHC’s Department of Oncology, therefore limiting the external validity of this study’s 
conclusions to reflect the  cancer rehabilitation  and its  patients in  everyday  practice (Steckler 
and McLeroy, 2008). 
 There is a limited availability of potential methodological designs for the three particular 
patient groups. A lack of control group for comparison makes it dificult to infer efect. Therefore, 
the next step would be to create control or contrast groups, although some patients only have a 
few months to live and withholding treatments would not be ethical. An option could be to use 
the  wait-listed  patients  as  controls in  a randomized  controled trial (Zernicke  et  al., 2014), to 
determine the unique efect of the CARE program. 
 This study has a retrospective design, with the main disadvantage of limited control over 
data  colection.  The  existing  data  was, in  certain instances, incomplete  or inconsistently 
measured  between  patients. The impact  of  missing  data in  quantitative  studies  has  serious 
implications of biased estimates of parameters, loss of information, decreased statistical power, 
increased  standard  errors,  and  weakened generalizability of findings (Dong  and  Peng,  2013). 
The scientific community is working on minimizing missing data by modifying study/trial design 
and how the trials are conducted. To ilustrate, just simplifying trial participation for patients, their 
caregivers,  and those  conducting the trials  might increase  program  completion  and  data 
colection. Despite the fact that there are many statistical analyses that accommodate missing 
data, (e.g., nonresponse  by  multiple imputation) it would be beneficial to identify possible 
paterns for  missing  data  when  planning  a  clinical trial/study.  Simple  modifications to the trial 
design may definitely minimize missing data (Kurland et al., 2012). 
 The time  period, in  days,  between the FU appointments of the patients participating in 
the CARE  program was also not consistent, therefore making it dificult to compare data and 
draw out conclusions with great statistical power. To overcome this issue and calculate changes 
over the duration of the FUs, data was truncated into 2-week windows of assessment. However, 
data truncation raises its own set of limitations, though it has litle efects on statistical power, it 
can afect linear relations between time and HRQoL outcome measures (Ulrich et al., 1994). 
 The colected outcome data in those patients completing the program was assessed to 
get  an idea  on the impact  of this type  of intervention.  Any  sort  of FU outcome data in those 
patients  not  completing the  program  might  have  been  equaly  helpful in  understanding  how 
these patients difered, in terms of disease deterioration, from those completing the program. 
Lastly, *possible reasons for having a significant main efect of pathway but no specific 
group diferences  after  performing the  posthoc tests:  1)  a  borderline  main  efect (e.g., 
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p=0.04999999 or p=0.050); 2) not enough people in the population sample to detect a posthoc 
diference (especialy if this finding is in some of the FU data where there was a significant drop 
of); 3) the possibility of having a lot of variability around the mean for each group (which if you 
don't have a lot of people in your group, this could be happening); 4) a main efect which is due 
to  error, given the  amount  of  analyses  performed this  could  be  a remote  possibility. 
Theoreticaly, 5 out of 100 completed analyses should be significant by chance so it could be a 
function  of  multiple tests.  However,  we  did  adjust for  multiple  comparisons in the  analyses  so 
that seems highly unlikely. 
10.5 Conclusion  
 The interventions of the CARE program, where the multidisciplinary team of health care 
professionals assessed, evaluated and provided personalized advice to the patients, did show 
some significant and meaningful trends of progress in self-reported, HRQoL outcome measures 
of overal malnutrition and appetite status for the cancer patients from al three pathways, within 
a  one  year time  period. The  data  colected throughout  2014 confirm that the HRQoL and 
symptom profile can vary significantly across cancer patients at diferent stages of their disease 
trajectories.  Our results reinforce the  need for  wel-controled  and randomized  clinical trials to 
confirm  any  benefits  of interdisciplinary  cancer rehabilitation  programs for  patients  and their 
families. Rehabilitation programs need to be organized around those characteristics in order to 
personalize possible future interventions and significantly impact on the performance and QoL 
of cancer patients. 
10.6 Future Directions 
Certain  ways to improve the  data  colection  of  questionnaires from  visit to  visit  and 
prepare  a  more  eficient  cancer rehabilitation  program  with  more focused  and  specialized 
interventions  wil folow.  A  main finding from this retrospective  chart review  was that there 
weren’t  many  colected  and  complete  sets  of initial  and  end  program  questionnaires.  The 
majority of patients completed an initial set of questionnaires, as they should, however, very few 
completed  an initial  and  end  set  of  questionnaires.  Reasons for the later include  a  variety  of 
situations,  either: the  questionnaires  weren’t  handed to the  patient  on the  day  of their  end 
evaluation, the patients never came to the clinic for their end visit, patients passed away before 
having their  end  evaluation  or  patients  were  not  wel  suited for the CARE  program and were 
referred elsewhere. Moving forward, patients, regardless of stream, should come in for an initial 
visit, folowed by two to three FU visits, and lastly an end visit. Once the patient is done with this 
“new”  program  and  stil  needs to  be  seen, they  can  either:  be referred to  another  clinic  beter 
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suited to  meet their  needs (e.g.,  psycho-social  oncology,  paliative  day  hospital, lymphedema 
program, survivorship program, etc.); schedule another appointment with a specific member of 
the CARE program for targeted interventions (e.g., if the patient only needs help with physical 
rehabilitation, then they schedule to meet the physiotherapist alone versus an appointment with 
the entire team); or re-enrol in the 4-5 visit cancer rehab program (e.g., if they need more help 
from the entire team). This way al patients have a pre-determined start and end visit date and 
al the required HRQoL outcome measures get colected, to adequately assess the impact of the 
CARE program on QoL status of its patients. 
 Another important addition to the CARE program, would be to assess patient satisfaction 
using the validated FACIT-TS-PS questionnaire (Peipert et al., 2014) pre- and post-program. It 
would  be  a  great  way to retrieve information  on  how the CARE  program is received from the 
perspective  of the  patients.  The  FACIT-TS-PS is  a relatively  new  developed treatment 
satisfaction tool that  measure the  health  care  experience during therapy,  or in this  case 
rehabilitation interventions, for  chronic ilness.  The  questionnaire is  composed  of the folowing 
subscales: explanations, interpersonal, comprehensive care, technical quality, decision-making, 
nurses, trust, and overal satisfaction, where items are scored using a 5-point system (0, not at 
al; 1, a litle; 2, somewhat; 3, quite a bit; 4, very much) (Peipert et al., 2014). 
 From  my  personal  experience  with the CARE  program, there  seems to  be  a  gap 
between  great  verbal  patient feedback (concerning their involvement  with the  program  and 
interaction  with the interdisciplinary team)  and  minimal  changes in their QoL status scores. 
Thus, it  would  be  very interesting  and informative to  perform  a  more  comprehensive 
investigation  on the  benefits  and/or  advantages  of  patient  participation.  Perhaps,  brief  patient 
interviews  can  be  conducted  at  various  points throughout the  program, to  determine  possible 
reasons for  patient  atendance,  despite their  own  acknowledgment  of  physical  and 
psychological deterioration.  
 A  great  clinical  service  such  as the CARE  program must adapt, be responsive and 
personalize to the  patients’  needs,  but  perhaps there  should  be  more  of  an  emphasis  on 
program completion or non-completion that is worth considering. For instance, in a clinical trial 
seting, completion is considered essential for outcome data and is a fundamental indicator of 
success. For patients with advanced cancer, CRP level and perceived strength are shown to be 
useful prognostic indicators for the ability to complete an interdisciplinary rehabilitation program 
(Chasen  et  al.,  2013).  These indicators  can  be  used to  assist in  patient  selection for 
rehabilitation and in directing patients to appropriate resources. Common to several successful 
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cancer rehabilitation program completion, is a fixed program duration (whether it be a 6-week or 
3-month long program) and rigid, scheduled FU visits. Earlier re-evaluation of sick patients and 
less waiting between FUs visits could potentialy lead to less dropouts and a higher number of 
subjects  completing the  program. Perhaps,  asking the  patients to fil  out five HRQoL 
questionnaires,  before  being  seen  by the CARE team, during their initial and end visit is too 
physicaly and mentaly demanding on the patients. Another suggestion: implementing a patient-
oriented goal seting, in addition to the goals that the rest of the health care team is seting for 
the patient, what do the patients what to improve on. 
 Are the patients actualy taking the advice given by the team?  Should the CARE team 
find  more  objective  ways  or  measures  of  compliance from  exercise  programs  and  dietary 
advice?  A  novel  and futuristic  approach to track if  patients  are  actualy folowing the  given 
advice, on a daily basis, is for the CARE program to develop an app (free download on smart 
phones,  which the  majority  of  patients  have).  This  could  be  an  app  where  each  health  care 
professional creates a check list of advice they are giving to the patient at each visit. Afterwards, 
al the patient has to do at home is check of which items on the list they are actualy completing, 
on their phones, on a daily basis. 
 Interesting future  projects  or  additions to this  project include:  discovering reasons for 
program  dropouts  by  making  FU phone cals to those  who  dropped  out;  determining if the 
patients  who  completed the CARE  program resulted in less than average paliative care or 
emergency  hospitalization  compared to  cancer  patients  who  did  not  undergo  a rehabilitation 
program; determine if the government wil save more money by investing in cancer rehabilitation 
programs  now,  which  may later  prevent,  delay  or  minimize in-patient  hospitalization. Is the 
CARE team being efective in terms of changing the behavior of their patients? Wil efectively 
modifying the  behavior  of the  patients,  alow them to  adopt  healthier lifestyle  changes  and 
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12.2 Appendix B: Description of the Three Rehabilitation Pathways 
 
RESTORATIVE REHABILITATION 
Prognosis No signs of active disease 
Patient 
Population 
- Patient is experiencing problems secondary to cancer and/or its 
treatments such as deconditioning, fatigue, weakness, nutritional and 
digestive problems or cognitive loss requiring an interdisciplinary 
approach (Physician-MD, Nurse-RN, Occupational Therapist-OT, 
Physical Therapist-PT, Dietitian-NUT) 
- Patient has been seen for post treatment evaluation by oncology and 
is at least 1 month after treatment is completed 
Goals - Optimize physical, nutritional and functional status 
- Return to usual activity 
- Minimize impact of cognitive dysfunction in daily living 
- Educate and empower patients to make healthy life choices 
Assessment 
Tools 




- 6 min walk 
- Sit to stand 
- SLS (Single Leg Stand) 
- Modified CHAMPS 
- Blood work (SMA-10, CRP, albumin, CBC, Testosterone) 
- Hand grip – 1 year pilot 
- Mini-Cog – 1 year pilot 
- FSI - 1 year pilot 
As needed: 
- MOCA, Bels-test, Trail-making 
- Blood work 
- Pitsburgh Sleep Quality Index 
- Semmes Weinstein monofilament test 






- 6 min walk 
- Sit to stand 
- SLS 
- Modified CHAMPS 
- MOCA if previously completed, 
- Pitsburgh Sleep Quality Index if previously completed, for 
comparison 
- Hand grip – 1 year pilot 
- FSI - 1 year pilot 






































Prognosis 6 months or greater, patients with active disease 
Patient 
Population 
- Patient is experiencing problems secondary to cancer and/or its 
treatments such as deconditioning, fatigue, weakness, nutritional 
and digestive problems or cognitive loss requiring an 
interdisciplinary approach (Physician, Nurse, Occupational 
Therapist, Physical Therapist, Dietitian) 
- Patients with active disease undergoing treatment or not 
Goals - Optimize physical, nutritional and functional status  
- Minimize impact of cognitive dysfunction in daily living  
- Educate and empower patients to make healthy life choices 




- 6 min walk 
- Sit to stand 
- SLS (Single Leg Stand) 
- Blood work (SMA-10, CARE, albumin, CBC,) 
- Hand grip – 1 year pilot 
- Mini-Cog – 1 year pilot 
- FSI - 1 year pilot 
As needed: 
- MOCA, Bels-test, Trail-making 
- Blood work (testosterone, etc…) 
- Pitsburgh Sleep Quality Index 









- 6 min walk 
- Sit to stand 
- SLS 
- Modified CHAMPS 
- MOCA if previously completed, for comparison 
- Pitsburgh Sleep Quality Index, if previously completed, 
for comparison 
- Hand grip – 1 year pilot 
- FSI - 1 year pilot 
- Blood work (SMA-10, CARE, albumin, CBC, 
Testosterone) 
 


































Timeline 2 – 4 months 
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CACHEXIA 
Prognosis Non-curative intent / Greater than 3 months 
Patient 
Population 
- Patients with inoperable/incurable/metastatic cancer presenting with 
weight loss, anorexia and indicators of abnormal metabolism 
(anemia, CARE, hypoalbuminemia, increased tumor markers, 
etc…) 
- ECOG 1 or 2  
- Pain control is not primary concern 
Goals - To optimize nutritional and functional status  
- Identify and minimize metabolic abnormalities associated with 
cachexia  
- Inform and empower the patient to act on their nutritional status. 




- Blood work (SMA-10, CARE, albumin, CBC, TSH, LFTs) 
- Vital signs 
- Hand grip – 1 year pilot 
- Mini-Cog – 1 year pilot 
- FSI if fatigue is > 4 on ESAS – 1 year pilot 
As needed/feasible 
- Additional blood work (bioavailable testosterone) 
- OT/PT referral 





- Hand grip 
- Blood work (to be done on a monthly basis prior to clinic 
appointment) 
- Vital signs 
End-evaluation: 
- FSI if was done at the first visit – 1 year pilot 




















































     
 
 
Slide Retrieved from Powerpoint Presentation: 
Vigano, AAL. (2013). The MUHC Cachexia Clinic: From Staging to Managing Nutritional and 








































































Restorative Supportive Cachexia 
Bio-psycho-social evaluation 
Clarify understanding of 
disease, and goals of FU 
Reinforce importance of 
recommended oncology FU 
 
Clarify understanding of disease, goals of treatment and 
care. 
Encourage seting realistic goals. 
 
Vital signs 
Review current medication list, current usage and organization  
Symptom assessment: 
Re pain, fatigue, GI and other symptoms: 
-Assess localization, intensity, qualily, frequency & duration, relieving and aggravating 
factors, associated symptoms 
-Efect on functional capacity and quality of life 
-Efectiveness of treatment 
-Side efects or complications of treatment 
-Contact number in order to report escalation of symptoms, ineficacity of treatment or side 
efects of treatment 
Re sleep disturbances : PQSI 
Re psycho-social distress: Assess for anxiety, depression, coping in patient and caregiver 
Re sexuality issues: Assess for dificulties in resuming usual sexual activity and/or adapting 
to change in body image 
 
Teaching/Education 
Identify information needs 
Reinforce understanding the cause of symptoms, rationale for intervention, use of 
medication, and side efects of medication 
Reinforce when to contact re. symptoms, provide contact number to cal if needed 
Re pain: Encourage use of pain journal 
Re fatigue: Reinforce rest/activity balance, seting priorities, realistic expectations. 
Reinforce directives given by ot and pt 
Re sleep: Review sleep hygiene 
 
Support 
-Active listening, validate feelings, normalize experience, commend eforts and strengths, 
prompt to identify strengths. 
Re sexuality issues: Validate their concerns, permission to discuss 
Re isolation or care giver burden: Refer to social services, CLSC and other community 
agencies. 
Coordination 
- Contact number for patients re symptoms, prescriptions, appointments, other concerns. 
-Triage of new referrals, booking appointments, clinic schedule,  
-Contact number for rehab/cachexia team. 
-In colaboration with MD and team, organize referrals to CLSC, PSO, SW, Pastoral care etc 
















to regain muscle mass and 
strength 
 




progressive walking program, biking, and/or return to pt’s 
usual cardio training program 
 
Light training: using 
slowly progressive 







Address musculoskeletal issues using manual therapy, ROM ex’s, specific 






Facilitate progressive return 
to physical activities such 
as heavy house work and 
pt’s usual phys. activities 
incl. sports, dance, yoga… 
 
 
Facilitate progressive and safe 
return to physical activities 
 
Facilitate safe 
participation in physical 
activities 
  




Fal-prevention techniques incl. prescription of walking 
aids, AFO’s, and education about neuropathies 
 
  
Empower pt. to be able to judge if phys. activities are 
appropriate for him/her 
 
 
Empower pt. to make life-
long healthy lifestyle 
choices and to make a 




Occupational Therapist Interventions: 
 
Restorative Supportive Cachexia 
 




Pain Management: Teach functional pain management strategies 
 
 
Self-care and daily Living : Provide adaptive aids to enable self-care and instrumental 
activities of daily living 
 
 
Safety: Assess fal risk and teach fal prevention techniques 
 
  
Safety: Assess need for home equipment and services 
Monitor patient’s functional status, and if need be, assist to 
transition the patient to appropriate living environment 
 
Experience of cancer: 
Discuss treatment 
experience, provide active 
listening and support 
Experience of cancer: 
Discuss cancer experience 
and help patient adapt to 
permanent life changes, 
provide active listening and 
support 
Experience of cancer: 
Discuss cancer experience 
and help patient adapt to 
permanent life changes, 




Functional goal: Assist 




Functional goal: Assist with 




Level of activity: 
- Improve activity levels 
- Simplify work or school 
related tasks 
- Enable meaningful 
activities 




Level of activity: 
- Maintain/Improve activity 
levels 
- Help patient work through 
activity or role losses 
- Enable meaningful activities 
- Teach strategies to 
compensate for decreased 
cognition 
 
Level of activity: 
- Slow down functional 
decline 
- Simplify self-care and 
leisure tasks and help 
patient work through activity 
or role losses 
- Enable meaningful light 
activities 







- For al interventions goals are created with the patient and family in order to meet their needs 
- Patients and families are empowered to make their own decisions. Individual food preferences 
are respected whether they be cultural, religious, personal or otherwise. However, in instances 
where current intake is inadequate or suboptimal the patient wil be informed and goals changed 
accordingly. 
- A summary of discussion with clear and specific goals  are  given to  patient  at the  end  of the 
session. 
- Al patients are provided contact information and are encouraged to cal with questions and 
concerns. 
Restorative Supportive Cachexia 
Promote weight gain/maintenance: Using high energy, high protein diet, supplements 
and modification of usual eating paterns and habits. 
Diabetes (including hypoglycemia): Using, “Just the Basics” for Diabetes, menu 
modification adapted for patients’ treatment phase and needs, dietary management of 
hypoglycemia, review of proper medication usage and discussion of discrepancies with 
MD, supplement use if applicable. 
Nausea and vomiting: Using “dietary management of nausea”, recommendations on 
remaining hydrated, homemade oral rehydration solution, modification of usual eating 
paterns and habits and revision of anti-emetic and prokinetic agent usage. 
Diarrhea: Using “dietary management of diarrhea”, low fiber diet, recommendations on 
remaining hydrated, homemade oral rehydration solution. 
Constipation: Using “dietary management of constipation with guide to high fiber 
foods”, fluid recommendations and revision of laxative use. 
Food security: Limited referral to community food access programs, discussion with 
team and referral to social worker as needed. 
Complimentary therapy/alternative medicine: Revision of natural health product 
usage for safety and eficacy along with traditional medicine using existing standards 
and references as wel as alerting team to any potential problems. Respecting patients’ 
wishes to engage in safe use of these therapies and to empower their choices. 
Demystify their usage. 
Promote weight 
loss/maintenance: Using 
Canada’s Food Guide to 
Healthy Eating, “Eating Wel 
After Cancer Treatment”, 
modification of usual eating 




 Mucositis: Using, “tips to manage dry mouth or thick 
saliva”, “tips to manage sore mouth or throat”, revision 
of oral hygiene and soft solid diet. 
 Taste changes: Using, “tips to manage taste or smel 
changes”, revision of oral hygiene, homemade mouth 
rinse recipe and menu modification. 
 Food safety: Using, “food safety during cancer” and 
alerting patient as to the safe usage of probiotics. 
However, patients typicaly receive food safety 
treatment prior to coming to cancer rehabilitation. 
 Dysphagia: Diet adapted based on type of dysphagia, 
instruction on modifying texture and consistency of 
solids and liquids, provide contact information for 
dysphagia product suppliers, enteral nutrition, 
discussion and FU with team OT with possible referral 




























12.5 Appendix E: Sample Questionnaires 
 






Image retrieved from: 
htp:/pt-global.org/?page_id=13 












Edmonton Symptom Assessment System (ESAS): 
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Fatigue Symptom Inventory (FSI): 
       
FSI 
For each of the folowing, circle the one number that best indicates how that item 
applies to you. 
 
1. Rate your level of fatigue on the day you felt most fatigued during the past week: 
0 1 2 3 4 5 6 7 8 9 10 
Not at al As fatigued 
fatigued as I could be 
 
2. Rate your level of fatigue on the day you felt least fatigued during the past week: 
0 1 2 3 4 5 6 7 8 9 10 
Not at al As fatigued 
fatigued as I could be 
 
3. Rate your level of fatigue on the average during the past week: 
0 1 2 3 4 5 6 7 8 9 10 
Not at al As fatigued 
fatigued as I could be 
 
4. Rate your level of fatigue right now: 
0 1 2 3 4 5 6 7 8 9 10 
Not at al As fatigued 
fatigued as I could be 
 
5. Rate how much, in the past week, fatigue interfered with your general level of activity: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
interference interference 
 
6. Rate how much, in the past week, fatigue interfered with your ability to bathe 
and dress yourself: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
interference interference 
 
7. Rate how much, in the past week, fatigue interfered with your normal work 
activity (includes both work outside the home and housework): 
0 1 2 3 4 5 6 7 8 9 10 








Fatigue Symptom Inventory (FSI) continued       
 
For each of the folowing, circle the one number that best indicates how that item applies 
to you. 
 
8. Rate how much, in the past week, fatigue interfered with your ability to concentrate: 
 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
interference interference 
 
9. Rate how much, in the past week, fatigue interfered with your relations with other 
people: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
interference interference 
 
10. Rate how much, in the past week, fatigue interfered with your enjoyment of life: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
interference interference 
 
11. Rate how much, in the past week, fatigue interfered with your mood: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
interference interference 
 
12. Indicate how many days, in the past week, you felt fatigued for any part of the day: 
0 1 2 3 4 5 6 7 
Days       Days 
 
13. Rate how much of the day, on average, you felt fatigued in the past week: 
0 1 2 3 4 5 6 7 8 9 10 
None of The entire 
the day day 
 
14. Indicate which of the folowing best describes the daily pattern of your fatigue in the 
past week: 
0 1 2 3 4 
Not at al Worse in Worse in Worse in No consistent daily 
fatigued the morning the afternoon the evening pattern of fatigue 
 
 
Fatigue Symptom Inventory, Mofit Cancer Center and University of South Florida, Tampa, 
FL ©1998 
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Distress Screening Tool (DST): 
 
















12.6 Appendix F: Result Tables 3n-3fffff 
 
Table 3n. Fixed Efects Table of FSI Variable Normal work activity interference PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Normal work activity interference 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 97 0.31 0.734 
Time 1 10 9.18 0.013 
Pathway * Time 2 10 2.47 0.134 
Age 1 97 1.91 0.170 
Sex 1 97 1.15 0.287 
On Treatment 1 97 0.04 0.844 
Number of FUs 1 97 0.00 0.985 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
no interference ; 10 = 
extreme interference) 
 
Normal work activity 
interference 
Restorative 0 4.5 ± 0.8 
Restorative 1 2.3 ± 0.9 
Supportive 0 4.1 ± 0.6 
Supportive 1 4.1 ± 1.3 
Cachexia 0 5.2 ± 0.5 







Table 3p. Fixed Efects Table of FSI Variable Relations with other people interference 
PRE/POST Program 
 
Type 3 Tests of Fixed Effects Relations with other people interference 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 95 0.48 0.620 
Time 1 10 6.68 0.027 
Pathway * Time 2 10 0.41 0.673 
Age 1 95 0.92 0.340 
Sex 1 95 0.03 0.863 
On Treatment 1 95 0.04 0.840 
Number of FUs 1 95 0.06 0.807 
 







 Adjusted Mean ± SE 
(Scores range from 0 = 
no interference ; 10 = 
extreme interference) 
 
Normal work activity 
interference 
Restorative 0 2.3 ± 0.7 
Restorative 1 1.4 ± 0.8 
Supportive 0 3.7 ± 0.5 
Supportive 1 2.0 ± 1.1 
Cachexia 0 3.7 ± 0.4 









Table 3r. Fixed Efects Table of FSI Variable Enjoyment of life interference PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Enjoyment of life  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 95 0.85 0.429 
Time 1 10 10.11 0.010 
Pathway * Time 2 10 0.27 0.768 
Age 1 95 0.09 0.761 
Sex 1 95 1.71 0.194 
On Treatment 1 95 0.33 0.566 
Number of FUs 1 95 0.24 0.628 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
no interference ; 10 = 
extreme interference) 
 
Enjoyment of life  
Restorative 0 3.1 ± 0.8 
Restorative 1 1.7 ± 0.9 
Supportive 0 4.9 ± 0.6 
Supportive 1 2.8 ± 1.2 
Cachexia 0 4.7 ± 0.5 












Table 3t. Fixed Efects Table of FSI Variable Mood interference PRE/POST Program 
 
Type 3 Tests of Fixed Effects Mood interference  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 97 0.62 0.540 
Time 1 11 3.67 0.084 
Pathway * Time 2 11 0.45 0.653 
Age 1 97 2.32 0.131 
Sex 1 97 1.72 0.193 
On Treatment 1 97 0.01 0.925 
Number of FUs 1 97 0.06 0.805 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
no interference ; 10 = 
extreme interference) 
 
Mood interference  
Restorative 0 3.0 ± 0.7 
Restorative 1 2.2 ± 0.9 
Supportive 0 4.2 ± 0.5 
Supportive 1 3.5 ± 1.2 
Cachexia 0 4.5 ± 0.5 













Table 3v. Fixed Efects Table of FSI Variable Activity interference PRE/POST Program 
 
Type 3 Tests of Fixed Effects Activity interference  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 96 1.21 0.302 
Time 1 11 6.41 0.028 
Pathway * Time 2 11 0.34 0.719 
Age 1 96 0.14 0.710 
Sex 1 96 1.20 0.276 
On Treatment 1 96 0.78 0.381 
Number of FUs 1 96 0.05 0.817 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
no interference ; 10 = 
extreme interference) 
 
Activity interference  
Restorative 0 3.7 ± 0.7 
Restorative 1 2.5 ± 0.9 
Supportive 0 5.2 ± 0.5 
Supportive 1 4.1 ± 1.0 
Cachexia 0 5.5 ± 0.4 














Table 3x. Fixed Efects Table of FSI Variable Concentration interference PRE/POST Program 
 
Type 3 Tests of Fixed Effects Concentration interference  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 95 1.04 0.356 
Time 1 10 9,68 0.011 
Pathway * Time 2 10 2.53 0.129 
Age 1 95 1.06 0.307 
Sex 1 95 0.58 0.449 
On Treatment 1 95 0.02 0.891 
Number of FUs 1 95 1.08 0.301 
 







Adjusted Mean ± SE 
(Scores range from 0 = 





Restorative 0 2.9 ± 0.7 
Restorative 1 2.2 ± 0.9 
Supportive 0 4.0 ± 0.5 
Supportive 1 2.9 ± 1.2 
Cachexia 0 4.0 ± 0.5 












Table 3z. Fixed Efects Table of FSI Variable Interference with the ability to self-bathe and 
dress PRE/POST Program 
 
Type 3 Tests of Fixed Effects Ability to self-bathe and dress  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 97 0.40 0.671 
Time 1 11 4.45 0.059 
Pathway * Time 2 11 0.28 0.762 
Age 1 97 0.01 0.943 
Sex 1 97 0.26 0.614 
On Treatment 1 97 0.07 0.792 
Number of FUs 1 97 0.24 0.624 
 







 Adjusted Mean ± SE 
(Scores range from 0 = 
no interference ; 10 = 
extreme interference) 
 
Interference with the 
ability to self-bathe and 
dress 
Restorative 0 1.9 ± 0.7 
Restorative 1 1.4 ± 0.8 
Supportive 0 2.1 ± 0.5 
Supportive 1 1.2 ± 0.8 
Cachexia 0 2.8 ± 0.5 









Table 3bb. Fixed Efects Table of FSI Variable Most Fatigued PRE/POST Program 
 
Type 3 Tests of Fixed Effects Most Fatigued  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 97 1.35 0.263 
Time 1 11 4.78 0.051 
Pathway * Time 2 11 0.14 0.873 
Age 1 97 2.25 0.137 
Sex 1 97 0.38 0.540 
On Treatment 1 97 0.05 0.825 
Number of FUs 1 97 0.54 0.464 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
not at al fatigued ; 10 = 
as fatigued as I can be) 
 
Most Fatigued 
Restorative 0 5.6 ± 0.6 
Restorative 1 3.5 ± 0.8 
Supportive 0 6.7 ± 0.4 
Supportive 1 5.3 ± 1.1 
Cachexia 0 6.5 ± 0.4 













Table 3dd. Fixed Efects Table of FSI Variable Average fatigue PRE/POST Program 
 
Type 3 Tests of Fixed Effects Average fatigue 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 97 2.46 0.091 
Time 1 11 3.96 0.072 
Pathway * Time 2 11 0.54 0.596 
Age 1 97 0.14 0.709 
Sex 1 97 0.98 0.324 
On Treatment 1 97 0.45 0.503 
Number of FUs 1 97 0.74 0.393 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
not at al fatigued ; 10 = 
as fatigued as I can be) 
 
Average fatigue 
Restorative 0 3.9 ± 0.5 
Restorative 1 2.1 ± 0.7 
Supportive 0 5.0 ± 0.4 
Supportive 1 3.8 ± 0.9 
Cachexia 0 5.0 ± 0.3 











Table 3f. Fixed Efects Table of FSI Variable Daily fatigue PRE/POST Program 
 
Type 3 Tests of Fixed Effects Daily fatigue  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 95 1.30 0.277 
Time 1 9 13.36 0.005 
Pathway * Time 2 9 0.15 0.860 
Age 1 95 2.08 0.152 
Sex 1 95 1.13 0.291 
On Treatment 1 95 1.56 0.215 
Number of FUs 1 95 0.01 0.936 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
none of the day ; 10 = 
the entire day) 
 
Daily fatigue  
Restorative 0 3.6 ± 0.7 
Restorative 1 1.5 ± 0.9 
Supportive 0 5.6 ± 0.5 
Supportive 1 3.0 ± 1.2 
Cachexia 0 5.2 ± 0.4 













Table 3hh. Fixed Efects Table of FSI Variable Numbers of days fatigued in the past week 
PRE/POST Program 
 
Type 3 Tests of Fixed Effects Numbers of days fatigued in the past week  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 94 0.34 0.715 
Time 1 10 10.18 0.010 
Pathway * Time 2 10 0.48 0.632 
Age 1 94 1.43 0.235 
Sex 1 94 0.96 0.330 
On Treatment 1 94 1.12 0.292 
Number of FUs 1 94 0.06 0.804 
 







Adjusted Mean ± SE 
(Scores range from 0 = 
0 days ; 7 = 7 days) 
 
Numbers of days 
fatigued in the past 
week 
Restorative 0 4.3 ± 0.6 
Restorative 1 3.4 ± 0.7 
Supportive 0 5.3 ± 0.4 
Supportive 1 3.6 ± 0.9 
Cachexia 0 5.4 ± 0.4 












Table 3j. Fixed Efects Table of FSI Variable Daily pattern of fatigue PRE/POST Program 
 
Type 3 Tests of Fixed Effects Daily pattern of fatigue  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 95 0.17 0.846 
Time 1 10 0.22 0.650 
Pathway * Time 2 10 0.07 0.931 
Age 1 95 0.15 0.701 
Sex 1 95 0.06 0.804 
On Treatment 1 95 0.40 0.530 
Number of FUs 1 95 1.17 0.283 
 







Adjusted Mean ± SE 
(Scores 0 = not at al 
fatigued; 1= worse in 
the morning; 2= worse 
in the afternoon; 
3=worse in the evening; 
4= no consistent daily 
pattern of fatigue) 
 
Daily pattern of fatigue 
Restorative 0 3.6 ± 0.3 
Restorative 1 3.4 ± 0.4 
Supportive 0 3.6 ± 0.2 
Supportive 1 3.3 ± 0.6 
Cachexia 0 3.7 ± 0.2 








Table 3l. Fixed Efects Table of DST Variable Distress thermometer PRE/POST Program 
 
Type 3 Tests of Fixed Effects Distress thermometer 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 4.52 0.013 
Time 1 8 1.99 0.196 
Pathway * Time 2 8 2.00 0.198 
Age 1 102 4.18 0.044 
Sex 1 102 0.44 0.509 
On Treatment 1 102 1.24 0.268 
Number of FUs 1 102 0.08 0.782 
 











(0 = no distress ;  10 = 
extreme distress) 
Restorative 0 2.3 ± 0.7 
Restorative 1 -0.006 ± 0.9 
Supportive 0 4.0 ± 0.5 
Supportive 1 4.0 ± 1.1 
Cachexia 0 4.1 ± 0.4 











Table 3nn. Fixed Efects Table of DST Variable Worrying about friends/family PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Worrying about friends/family 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.76 0.177 
Time 1 8 0.05 0.821 
Pathway * Time 2 8 4.91 0.041 
Age 1 102 1.74 0.190 
Sex 1 102 0.27 0.603 
On Treatment 1 102 2.38 0.126 
Number of FUs 1 102 2.06 0.154 
 







Adjusted Mean (%) ± SE 





Restorative 0 40.6 ± 11.3 
Restorative 1 0.5 ± 18.6 
Supportive 0 51.4 ± 8.3 
Supportive 1 21.0 ± 23.2 
Cachexia 0 28.2 ± 7.1 











Table 3pp. Fixed Efects Table of DST Variable Work/School PRE/POST Program 
 
Type 3 Tests of Fixed Effects Work/School 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.34 0.268 
Time 1 8 0.02 0.898 
Pathway * Time 2 8 0.44 0.658 
Age 1 102 3.06 0.083 
Sex 1 102 1.76 0.187 
On Treatment 1 102 0.20 0.653 
Number of FUs 1 102 0.61 0.438 
 







Adjusted Mean (%) ± SE 




Restorative 0 28.3 ± 8.8 
Restorative 1 27.8 ± 15.9 
Supportive 0 15.6 ± 6.5 
Supportive 1 28.6 ± 20.3 
Cachexia 0 10.1 ± 5.5 











Table 3rr. Fixed Efects Table of DST Variable Weight PRE/POST Program 
 
Type 3 Tests of Fixed Effects Weight 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.13 0.879 
Time 1 8 0.98 0.352 
Pathway * Time 2 8 1.21 0.347 
Age 1 102 0.05 0.819 
Sex 1 102 0.88 0.349 
On Treatment 1 102 0.48 0.492 
Number of FUs 1 102 0.09 0.770 
 







Adjusted Mean (%) ± SE 




Restorative 0 41.8 ± 12.1 
Restorative 1 51.3 ± 22.3 
Supportive 0 40.7 ± 8.9 
Supportive 1 33.8 ± 28.2 
Cachexia 0 64.7 ± 7.6 











Table 3t. Fixed Efects Table of DST Variable Understanding my ilness and/or treatment 
PRE/POST Program 
 
Type 3 Tests of Fixed Effects Understanding my ilness and/or treatment  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.28 0.281 
Time 1 8 2.51 0.152 
Pathway * Time 2 8 1.82 0.223 
Age 1 102 5.04 0.027 
Sex 1 102 0.72 0.400 
On Treatment 1 102 10.41 0.002 
Number of FUs 1 102 0.41 0.524 
 







Adjusted Mean (%) ± SE 




ilness and/or treatment 
Restorative 0 30.7 ± 10.2 
Restorative 1 30.1 ± 13.6 
Supportive 0 23.3 ± 7.5 
Supportive 1 -10.0 ± 15.4 
Cachexia 0 26.3 ± 6.4 









Table 3vv. Fixed Efects Table of DST Variable Talking with the health care team PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Talking with the health care team 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.12 0.889 
Time 1 8 1.19 0.307 
Pathway * Time 2 8 0.08 0.924 
Age 1 102 0.92 0.340 
Sex 1 102 0.81 0.370 
On Treatment 1 102 0.40 0.529 
Number of FUs 1 102 0.14 0.705 
 







Adjusted Mean (%) ± SE 
(percentage of patients 
feeling distressed) 
 
Talking with the health 
care team 
Restorative 0 8.4 ± 8.1 
Restorative 1 1.2 ± 14.8 
Supportive 0 18.1 ± 6.0 
Supportive 1 3.6 ± 18.8 
Cachexia 0 12.7 ± 5.1 










Table 3xx. Fixed Efects Table of DST Variable Sleep PRE/POST Program 
 
Type 3 Tests of Fixed Effects Sleep 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.59 0.554 
Time 1 8 7.59 0.025 
Pathway * Time 2 8 0.37 0.705 
Age 1 102 0.74 0.392 
Sex 1 102 4.96 0.028 
On Treatment 1 102 0.08 0.781 
Number of FUs 1 102 0.23 0.630 
 







Adjusted Mean (%) ± SE 




Restorative 0 72.6 ± 11.5 
Restorative 1 20.4 ± 19.7 
Supportive 0 57.3 ± 8.5 
Supportive 1 8.6 ± 24.9 
Cachexia 0 34.7 ± 7.2 












Table 3zz. Fixed Efects Table of DST Variable Sadness PRE/POST Program 
 
Type 3 Tests of Fixed Effects Sadness 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.14 0.867 
Time 1 8 2.79 0.134 
Pathway * Time 2 8 0.56 0.594 
Age 1 102 1.58 0.212 
Sex 1 102 1.12 0.293 
On Treatment 1 102 0.34 0.559 
Number of FUs 1 102 0.49 0.484 
 







Adjusted Mean (%) ± SE 




Restorative 0 43.0 ± 12.4 
Restorative 1 24.9 ± 17.4 
Supportive 0 43.7 ± 9.1 
Supportive 1 40.5 ± 20.4 
Cachexia 0 50.6 ± 7.8 












Table 3bbb. Fixed Efects Table of DST Variable Meaning/purpose of life PRE/POST Program 
 
Type 3 Tests of Fixed Effects Meaning/purpose of life 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.54 0.587 
Time 1 8 1.80 0.217 
Pathway * Time 2 8 0.29 0.758 
Age 1 102 0.02 0.882 
Sex 1 102 1.61 0.207 
On Treatment 1 102 1.41 0.237 
Number of FUs 1 102 0.73 0.394 
 







Adjusted Mean (%) ± SE 
(percentage of patients 
feeling distressed) 
 
Meaning/purpose of life 
Restorative 0 22.2 ± 9.1 
Restorative 1 12.7 ± 16.3 
Supportive 0 17.6 ± 6.7 
Supportive 1 -12.3 ± 19.7 
Cachexia 0 14.9 ± 5.7 












Table 3ddd. Fixed Efects Table of DST Variable Making treatment decisions PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Making treatment decisions 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.68 0.192 
Time 1 8 0.38 0.552 
Pathway * Time 2 8 0.31 0.742 
Age 1 102 0.45 0.502 
Sex 1 102 0.63 0.429 
On Treatment 1 102 2.88 0.093 
Number of FUs 1 102 0.62 0.432 
 







Adjusted Mean (%) ± SE 





Restorative 0 29.2 ± 9.7 
Restorative 1 13.2 ± 17.0 
Supportive 0 11.0 ± 7.2 
Supportive 1 -6.9 ± 20.0 
Cachexia 0 27.2 ± 6.2 










Table 3ff. Fixed Efects Table of DST Variable Loss of interest in usual activities PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Loss of interest in usual activities 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.33 0.717 
Time 1 8 7.39 0.026 
Pathway * Time 2 8 0.58 0.582 
Age 1 102 0.75 0.388 
Sex 1 102 1.03 0.313 
On Treatment 1 102 1.13 0.290 
Number of FUs 1 102 0.72 0.399 
 







Adjusted Mean (%) ± SE 
(percentage of patients 
feeling distressed) 
 
Loss of interest in 
usual activities 
Restorative 0 22.0 ± 10.9 
Restorative 1 -18.7 ± 19.2 
Supportive 0 44.0 ± 8.1 
Supportive 1 -22.1 ± 2.8 
Cachexia 0 30.1 ± 6.9 










Table 3hhh. Fixed Efects Table of DST Variable Knowing about available resources 
PRE/POST Program 
 
Type 3 Tests of Fixed Effects Knowing about available resources 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.48 0.232 
Time 1 8 5.52 0.047 
Pathway * Time 2 8 3.53 0.080 
Age 1 102 0.09 0.760 
Sex 1 102 2.83 0.095 
On Treatment 1 102 0.00 0.996 
Number of FUs 1 102 1.00 0.320 
 







Adjusted Mean (%) ± SE 





Restorative 0 9.5 ± 10.1 
Restorative 1 8.9 ± 12.8 
Supportive 0 27.2 ± 7.4 
Supportive 1 23.3 ± 13.9 
Cachexia 0 25.8 ± 6.4 










Table 3jj. Fixed Efects Table of DST Variable Intimacy/sexuality PRE/POST Program 
 
Type 3 Tests of Fixed Effects Intimacy/sexuality 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.72 0.491 
Time 1 8 0.81 0.393 
Pathway * Time 2 8 0.35 0.716 
Age 1 102 4.71 0.032 
Sex 1 102 2.48 0.119 
On Treatment 1 102 0.33 0.569 
Number of FUs 1 102 0.11 0.745 
 







Adjusted Mean (%) ± SE 




Restorative 0 24.4 ± 8.6 
Restorative 1 13.1 ± 15.0 
Supportive 0 15.5 ± 6.4 
Supportive 1 -8.5 ± 17.7 
Cachexia 0 14.7 ± 5.5 












Table 3ll. Fixed Efects Table of DST Variable Frustation/anger PRE/POST Program 
 
Type 3 Tests of Fixed Effects Frustation/anger 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.59 0.210 
Time 1 8 0.03 0.866 
Pathway * Time 2 8 2.52 0.141 
Age 1 102 3.54 0.063 
Sex 1 102 0.18 0.671 
On Treatment 1 102 0.00 0.997 
Number of FUs 1 102 1.54 0.218 
 







Adjusted Mean (%) ± SE 




Restorative 0 29.9 ± 11.3 
Restorative 1 -3.0 ± 18.8 
Supportive 0 35.0 ± 8.3 
Supportive 1 18.3 ± 23.6 
Cachexia 0 28.5 ± 7.1 












Table 3nnn. Fixed Efects Table of DST Variable Finances PRE/POST Program 
 
Type 3 Tests of Fixed Effects Finances 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.13 0.875 
Time 1 8 4.54 0.066 
Pathway * Time 2 8 0.33 0.727 
Age 1 102 7.93 0.006 
Sex 1 102 0.10 0.747 
On Treatment 1 102 1.11 0.295 
Number of FUs 1 102 1.55 0.217 
 







Adjusted Mean (%) ± SE 




Restorative 0 28.7 ± 9.4 
Restorative 1 -2.3 ± 15.6 
Supportive 0 19.1 ± 6.9 
Supportive 1 6.9 ± 19.6 
Cachexia 0 20.8 ± 5.9 












Table 3ppp. Fixed Efects Table of DST Variable Fears/worries PRE/POST Program 
 
Type 3 Tests of Fixed Effects Fears/worries 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.25 0.780 
Time 1 8 1.42 0.267 
Pathway * Time 2 8 0.47 0.644 
Age 1 102 2.04 0.156 
Sex 1 102 0.15 0.702 
On Treatment 1 102 0.58 0.446 
Number of FUs 1 102 3.40 0.068 
 







Adjusted Mean (%) ± SE 




Restorative 0 31.6 ± 11.7 
Restorative 1 16.1 ± 17.1 
Supportive 0 41.6 ± 8.6 
Supportive 1 13.9 ± 20.4 
Cachexia 0 35.9 ± 7.4 












Table 3rr. Fixed Efects Table of DST Variable Coping PRE/POST Program 
 
Type 3 Tests of Fixed Effects Coping 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 2.69 0.072 
Time 1 8 0.10 0.756 
Pathway * Time 2 8 0.68 0.534 
Age 1 102 0.17 0.683 
Sex 1 102 1.28 0.261 
On Treatment 1 102 0.00 0.985 
Number of FUs 1 102 0.08 0.774 
 







Adjusted Mean (%) ± SE 




Restorative 0 16.1 ± 11.6 
Restorative 1 5.1 ± 17.3 
Supportive 0 46.0 ± 8.5 
Supportive 1 63.3 ± 20.9 
Cachexia 0 36.0 ± 7.3 












Table 3tt. Fixed Efects Table of DST Variable Constipation or diarrhea PRE/POST Program 
 
Type 3 Tests of Fixed Effects Constipation or diarrhea 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.30 0.278 
Time 1 8 0.09 0.773 
Pathway * Time 2 8 1.93 0.208 
Age 1 102 0.05 0.818 
Sex 1 102 0.48 0.489 
On Treatment 1 102 2.28 0.134 
Number of FUs 1 102 0.69 0.409 
 







Adjusted Mean (%) ± SE 





Restorative 0 31.7 ± 11.1 
Restorative 1 2.2 ± 19.3 
Supportive 0 31.5 ± 8.1 
Supportive 1 9.2 ± 24.5 
Cachexia 0 28.7 ± 7.0 










Table 3vvv. Fixed Efects Table of DST Variable Concentration/memory PRE/POST Program 
 
Type 3 Tests of Fixed Effects Concentration/memory 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.97 0.144 
Time 1 8 0.52 0.491 
Pathway * Time 2 8 1.28 0.329 
Age 1 102 0.14 0.706 
Sex 1 102 0.04 0.845 
On Treatment 1 102 2.98 0.088 
Number of FUs 1 102 5.16 0.025 
 







Adjusted Mean (%) ± SE 




Restorative 0 28.0 ± 8.7 
Restorative 1 13.3 ± 14.9 
Supportive 0 42.1 ± 7.7 
Supportive 1 0.0 ± 27.4 
Cachexia 0 37.5 ± 7.4 












Table 3xxx. Fixed Efects Table of DST Variable Changes in appearances PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Changes in appearances 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.68 0.510 
Time 1 8 1.73 0.224 
Pathway * Time 2 8 0.63 0.559 
Age 1 102 0.10 0.750 
Sex 1 102 14.9 0.0002 
On Treatment 1 102 0.00 0.951 
Number of FUs 1 102 0.57 0.453 
 







Adjusted Mean (%) ± SE 





Restorative 0 22.4 ± 10.1 
Restorative 1 21.9 ± 16.3 
Supportive 0 19.0 ± 7.5 
Supportive 1 -5.4 ± 18.2 
Cachexia 0 34.4 ± 6.5 










Table 3zzz. Fixed Efects Table of DST Variable Feeling a burden to others PRE/POST 
Program 
 
Type 3 Tests of Fixed Effects Feeling a burden to others 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.48 0.233 
Time 1 8 1.54 0.250 
Pathway * Time 2 8 0.71 0.522 
Age 1 102 1.04 0.311 
Sex 1 102 0.89 0.347 
On Treatment 1 102 0.50 0.480 
Number of FUs 1 102 1.40 0.240 
 







Adjusted Mean (%) ± SE 
(percentage of patients 
feeling distressed) 
 
Feeling a burden to 
others 
Restorative 0 24.7 ± 11.1 
Restorative 1 7.2 ± 16.9 
Supportive 0 25.5 ± 8.1 
Supportive 1 -6.2 ± 20.5 
Cachexia 0 36.6 ± 7.0 











Table 3bbbb. Fixed Efects Table of DST Variable Feeling alone PRE/POST Program 
 
Type 3 Tests of Fixed Effects Feeling alone  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 1.99 0.142 
Time 1 8 3.37 0.104 
Pathway * Time 2 8 0.64 0.550 
Age 1 102 0.13 0.724 
Sex 1 102 0.12 0.725 
On Treatment 1 102 0.00 0.973 
Number of FUs 1 102 1.85 0.177 
 







Adjusted Mean (%) ± SE 
(percentage of patients 
feeling distressed) 
 
Feeling alone  
Restorative 0 27.8 ± 9.6 
Restorative 1 18.7 ± 15.0 
Supportive 0 24.6 ± 7.1 
Supportive 1 12.7 ± 18.4 
Cachexia 0 11.4 ± 6.0 











Table 3dddd. Fixed Efects Table of DST Variable Accommodation PRE/POST Program 
 
Type 3 Tests of Fixed Effects Accommodation 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 102 0.05 0.952 
Time 1 8 0.54 0.482 
Pathway * Time 2 8 0.03 0.971 
Age 1 102 0.23 0.632 
Sex 1 102 0.49 0.487 
On Treatment 1 102 0.07 0.791 
Number of FUs 1 102 0.10 0.755 
 







Adjusted Mean (%) ± SE 




Restorative 0 3.2 ± 5.0 
Restorative 1 -1.6 ± 9.1 
Supportive 0 4.9 ± 3.7 
Supportive 1 -2.8 ± 11.6 
Cachexia 0 5.3 ± 3.1 










Table 3ff. Fixed Efects Table of m-CHAMPS Variable Sedentary Activity PRE/POST 
Program 
Type 3 Tests of Fixed Effects Sedentary Activity  
Effect Num DF Den DF F Value Pr > F 
Pathway 2 54 0.28 0.760 
Time 1 6 1.50 0.266 
Pathway * Time 2 6 0.33 0.729 
Age 1 54 0.01 0.933 
Sex 1 54 0.00 0.964 
On Treatment 1 54 2.20 0.143 
Number of FUs 1 54 0.43 0.513 
 











Restorative 0 35.2 ± 5.7 
Restorative 1 25.7 ± 7.0 
Supportive 0 37.3 ± 3.9 
Supportive 1 36.0 ± 11.6 
Cachexia 0 39.2 ± 1.9 












Table 3hhhh. Fixed Efects Table of m-CHAMPS Variable Light Activity PRE/POST Program 
Type 3 Tests of Fixed Effects Light Activity 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 54 1.34 0.271 
Time 1 6 6.30 0.046 
Pathway * Time 2 6 0.33 0.733 
Age 1 54 0.74 0.392 
Sex 1 54 0.06 0.808 
On Treatment 1 54 0.01 0.910 
Number of FUs 1 54 0.09 0.770 
 







(hrs) ± SE 
 
Light Activity 
Restorative 0 22.9 ± 3.9 
Restorative 1 33.4 ± 4.5 
Supportive 0 15.1 ± 2.7 
Supportive 1 22.6 ± 6.5 
Cachexia 0 17.4 ± 3.1 












Table 3jj. Fixed Efects Table of m-CHAMPS Variable Moderate Activity PRE/POST Program 
Type 3 Tests of Fixed Effects Moderate Activity 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 54    0.17 0.841 
Time 1 6    0.02 0.902 
Pathway * Time 2 6 0.50 0.632 
Age 1 54 0.03 0.864 
Sex 1 54 12.25 0.001 
On Treatment 1 54 1.94 0.169 
Number of FUs 1 54 0.00 0.963 
 











Restorative 0 6.8 ± 2.4 
Restorative 1 10.2 ± 3.1 
Supportive 0 10.8 ± 1.7 
Supportive 1 9.6 ± 5.4 
Cachexia 0 9.4 ± 1.9 












Table 3ll. Fixed Efects Table of m-CHAMPS Variable Heavy Activity PRE/POST Program 
 
Type 3 Tests of Fixed Effects Heavy Activity 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 54 0.75 0.479 
Time 1 6 0.02 0.884 
Pathway * Time 2 6 0.29 0.757 
Age 1 54 25.14 <0.0001 
Sex 1 54 4.90 0.031 
On Treatment 1 54 1.05 0.309 
Number of FUs 1 54 0.66 0.419 
 







(hrs) ± SE 
 
Heavy Activity 
Restorative 0 -0.2 ± 0.4 
Restorative 1 0.4 ± 0.4 
Supportive 0 0.7 ± 0.3 
Supportive 1 0.6 ± 0.7 
Cachexia 0 0.6 ± 0.3 













Table 3nnnn. Fixed Efects Table of ESAS variable Anxiety over 12 two-week intervals 
 
Random trend Model Type 3 Tests of Fixed Effects for Anxiety 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 1.78 0.172 
2 Week Block Time Intervals 1 93 0.02 0.881 
Pathway * 2 Week Block Time Intervals 2 179 0.57 0.567 
Age 1 179 0.21 0.648 
Sex 1 179 1.47 0.227 
On/Of Oncological Treatment 1 179 0.57 0.453 
 
Figure 4. Plot of ESAS anxiety score over time 












2-Week Block Time Intervals 





Table 3oooo. Fixed Efects Table of ESAS variable Depression over 12 two-week intervals 
 
Random Trend Model Type 3 Tests of Fixed Effects for Depression 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 0.22 0.801 
2 Week Block Time Intervals 1 93    0.00 0.961 
Pathway * 2 Week Block Time Intervals 2 179 0.27 0.762 
Age 1 179 0.00 0.971 
Sex 1 179 0.69 0.406 
On/Of Oncological Treatment 1 179 5.02 0.026 
 
Figure 5. Plot of ESAS depression score over time 











2-Week Block Time Intervals 





Table 3pppp. Fixed Efects Table of ESAS variable Drowsiness over 12 two-week intervals 
Random Trend Model Type 3 Tests of Fixed Effects for Drowsiness 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 2.47 0.087 
2 Week Block Time Intervals 1 93 1.45 0.231 
Pathway * 2 Week Block Time Intervals 2 179 0.25 0.782 
Age 1 179 0.03 0.857 
Sex 1 179 0.30 0.586 
On/Of Oncological Treatment 1 179 0.18 0.674 
 
Figure 6. Plot of ESAS drowsiness score over time 













2-Week Block Time Intervals 





Table 3qqqq. Fixed Efects Table of ESAS variable Fatigue over 12 two-week intervals 
Random Trend Model Type 3 Tests of Fixed Effects for Fatigue 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 2.31 0.102 
2 Week Block Time Intervals 1 93 1.78 0.185 
Pathway * 2 Week Block Time Intervals 2 179 0.64 0.531 
Age 1 179 0.60 0.442 
Sex 1 179 1.18 0.279 
On/Of Oncological Treatment 1 179 1.19 0.278 
 
Figure 7. Plot of ESAS fatigue score over time 














2-Week Block Time Intervals 





Table 3rrrr. Fixed Efects Table of ESAS variable Nausea over 12 two-week intervals 
Random Trend Model Type 3 Tests of Fixed Effects for Nausea 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 4.97 0.008 
2 Week Block Time Intervals 1 93 0.45 0.505 
Pathway * 2 Week Block Time Intervals 2 179 1.20 0.302 
Age 1 179 8.19 0.005 
Sex 1 179 6.65 0.011 
On/Of Oncological Treatment 1 179 0.02 0.885 
 
Figure 8. Plot of ESAS nausea score over time 



















2-Week Block Time Intervals 





Table 3ssss. Fixed Efects Table of ESAS variable Pain over 12 two-week intervals 
Random Trend Model Type 3 Tests of Fixed Effects for Pain 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 2.32 0.101 
2 Week Block Time Intervals 1 93 1.10 0.298 
Pathway * 2 Week Block Time Intervals 2 179 0.22 0.800 
Age 1 179 0.64 0.425 
Sex 1 179 3.08 0.081 
On/Of Oncological Treatment 1 179 5.70 0.018 
 
Figure 9. Plot of ESAS pain score over time 
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Figure 10. Plot of ESAS SOB score over time 
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Random Trend Model Type 3 Tests of Fixed Effects for SOB 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 178 4.09 0.018 
2 Week Block Time Intervals 1 93 0.47 0.493 
Pathway * 2 Week Block Time Intervals 2 178 0.35 0.702 
Age 1 178 2.38 0.124 
Sex 1 178 2.23 0.137 
On/Of Oncological Treatment 1 178 0.83 0.363 
	  121	  
Table 3uuuu. Fixed Efects Table of ESAS variable Wel-being over 12 two-week intervals 
Random Trend Model Type 3 Tests of Fixed Effects for Wel-being 
Effect Num DF Den DF F Value Pr > F 
Pathway 2 179 5.48 0.005 
2 Week Block Time Intervals 1 93 1.34 0.250 
Pathway * 2 Week Block Time Intervals 2 179 0.47 0.624 
Age 1 179 1.17 0.282 
Sex 1 179 1.27 0.262 
On/Of Oncological Treatment 1 179 0.76 0.384 
 
Figure 11. Plot of ESAS wel-being score over time 
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